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ABSTRACT 
 
Gene Therapy Provides Long-term Visual Function in a Pre-clinical Model of Retinitis 
Pigmentosa 
 
Katherine J. Wert 
 
Retinitis pigmentosa (RP) is a photoreceptor neurodegenerative disease. Patients with RP 
present with the loss of their peripheral visual field, and the disease will progress until there is a 
full loss of vision. Approximately 36,000 cases of simplex and familial RP worldwide are caused 
by a mutation in the rod-specific cyclic guanosine monophosphate phosphodiesterase (PDE6) 
complex. However, despite the need for treatment, mouse models with mutations in the alpha 
subunit of PDE6 have not been characterized beyond 1 month of age or used to test the pre-
clinical efficacy of potential therapies for human patients with RP caused by mutations in 
PDE6A.  
We first proposed to establish the temporal progression of retinal degeneration in a 
mouse model with a mutation in the alpha subunit of PDE6: the Pde6a
nmf363
 mouse. Next, we 
developed a surgical technique to enable us to deliver therapeutic treatments into the mouse 
retina. We then hypothesized that increasing PDE6α levels in the Pde6anmf363 mouse model, 
using an AAV2/8 gene therapy vector, could improve photoreceptor survival and retinal function 
when delivered before the onset of degeneration. Human RP patients typically will not visit an 
eye care professional until they have a loss of vision, therefore we further hypothesized that this 
gene therapy vector could improve photoreceptor survival and retinal function when delivered 
after the onset of degeneration, in a clinically relevant scenario.  
For each of these studies, we used histology, autofluorescence (AF) and infrared (IR) 
imaging to examine the appearance of the retinal cell layers and retinal pigment epithelium 
(RPE) that are affected in human RP patients. We also used electroretinograms (ERGs) to 
measure both photoreceptor-specific and global retinal visual function in the Pde6a
nmf363
 mice. 
For our gene therapy experiments, we utilized a vector with the cell-type-specific rhodopsin 
(RHO) promoter: AAV2/8(Y733F)-Rho-Pde6α, to transduce Pde6αnmf363 retinas after subretinal 
injection at either post-natal day (P) 5 or P21. We then monitored the effects of 
AAV2/8(Y733F)-Rho-Pde6α transduction over at least a quarter of the mouse lifespan.  
In the Pde6αnmf363 mutant mouse model of RP, we found that by 2 months of age the 
number of photoreceptor cell nuclei is roughly halved in comparison to the 1 month time-point, 
and this degeneration continues until all photoreceptor cell nuclei have undergone degeneration 
by 4 months of age. Additionally, both loss of cone cell function and RPE atrophy are present by 
5 months of age in these mice. After the development of a subretinal injection surgical 
procedure, we delivered the AAV2/8(Y733F)-Rho-Pde6α to the Pde6αnmf363 mice at either P5 or 
P21. We found that a single injection enhanced survival of photoreceptors and improved retinal 
function. At 6 months of age, the treated eyes retained photoreceptor cell bodies, while there 
were no detectable photoreceptors remaining in the untreated eyes. More importantly, the treated 
eyes demonstrated functional visual responses even after the untreated eyes had lost all vision. 
Despite focal rescue of the retinal structure adjacent to the injection site, global functional rescue 
of the entire retina was observed. We have also determined that subretinal transduction of this 
rod-specific transgene at P21, when approximately half of the photoreceptor cells have 
undergone degeneration, has similar efficacy in rescuing cone cell function long-term as 
transduction before disease onset, at P5.  
Therefore, we concluded that the Pde6a
nmf363
 mice mimic human RP caused by mutations 
in PDE6A. The establishment of the temporal and biochemical characteristics of photoreceptor 
neurodegeneration in the Pde6a
nmf363
 mice allows for future studies to test therapeutic options 
using this animal model, since the progression of RP can be compared to the established time-
course of degeneration. Additionally, the development of a standard method for performing 
subretinal injections allows for comparable results after this surgical technique is used to deliver 
gene therapy vectors into the perinatal mouse eye. Our gene therapy studies suggest that RP due 
to PDE6α deficiency in humans, in addition to PDE6β deficiency, is also likely to be treatable by 
gene therapy. Furthermore, AAV2/8(Y733F)-Rho-Pde6α is an effective gene therapy treatment 
that can be utilized in the clinical setting, in human patients who have lost portions of their 
peripheral visual field and are in the mid-stage of disease when they first present to an eye-care 
professional.
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Chapter 1: Background of Ophthalmology and Research in Retinitis Pigmentosa* 
*This chapter is adapted from a chapter currently in press: Wert, K.J., Lin, J.H. and Tsang, S.H. 
(2014) Cell-based therapy for retinal degenerative disease. Dev. Ophthalmol., Basel, Karger, 53, 
in press. 
 
PART I: THE EYE AND THE RETINA 
BRIEF OVERVIEW OF THE EYE 
The eye is a complex organ that provides information on the form, light intensity, and 
color reflected from objects. It is divided into two segments: anterior and posterior. The anterior 
segment consists of the cornea, lens, iris and ciliary body; whereas the posterior segment consists 
mainly of the vitreous, retina, and choroid (Figure 1; 1). The eye has been further divided into 
three primary layers: the outer, protective layer (the sclera and cornea), the middle, vascular and 
nutritive layer (the choroid, ciliary body and iris), and the inner, neural sensory layer (the retina) 
(2-3). Each layer has its importance; however, the focus in this review will be the retina. 
 
Figure 1. Schematic of the eye. Each of the major structures of the human eye as viewed from 
the side of the eye (4). 
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THE RETINA 
The retina is considered to consist of two layers; the outer retinal pigment epithelial 
(RPE) cell layer and the inner, sensory cell layer. The outermost layer, the RPE, is considered the 
retinal-blood barrier and acts primarily as protection for the inner cells of the retina. It is 
composed of a monolayer of columnar cells that provides nourishment and clears outer segment 
debris for the sensory photoreceptor cells (5-9). The RPE is polarized, so its cells have apical and 
basal regions. For each cell, there are ion-transporting activities and tight junctions to allow for 
control of intercellular communication and electrical potential differences between the two 
surfaces of the epithelium. This carefully regulates the RPE ion passage and phagocytic activity 
to and from, respectively, the inner sensory layer (3).  
The sensory layer of the retina is more complex than the RPE, and contains at least 15 
different types of neurons that form at least 38 distinct synapses with one another (3). There is an 
outer layer of light sensitive neurons, called the photoreceptor cells, followed by layers 
consisting of, in order from the photoreceptor cells inwards: Müller glial cells, amacrine cells, 
bipolar neurons, horizontal cells, and ganglion cells (Figure 2). When light enters the retina, it 
passes through each of these cell layers and is absorbed by the RPE. Before absorption, it is 
sensed by the photoreceptor cells, which activates a signaling cascade to the optic nerve for 
visual processing by the brain. 
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Figure 2. Schematic of the Neural Retina. Cartoon image of the neural retina depicting the 
many cellular layers, the retinal pigment epithelium, and the choroidal blood vessels. The legend 
notes the cell types by their corresponding colors and location in the retinal image. © Alton 
Szeto and Vinit Mahajan. 
 
The photoreceptor cells are highly important neuronal cells that consist of an outer 
segment (OS), an inner segment (IS), a cell body, and a synaptic terminal for neurotransmission 
to the second-order cells of the retina. The photoreceptor layer is composed of two specific types 
of photosensitive cells. First, the rod cells, which comprise approximately 97% of the retinal 
photoreceptors, and secondly, the cone cells, which make up the other 3% of the retinal 
photoreceptor cells in both mouse and human retinas. The IS of both photoreceptor cell types is 
comprised of ribosomes, mitochondria, and membranes that are used to assemble and transport 
opsin molecules to the OS discs (10). In the rod cells, the OS is characterized by invaginations of 
the plasma membrane at its base, which makes detached stacks of disc structures (10). Within the 
cones, on the other hand, the discs remain attached to the OS membrane. The RPE cells produce 
pseudopodia that continually renew these OS discs by separating the distal disc from the 
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remaining stack. These shed discs are then degraded by phagocytosis within the RPE, keeping 
the photoreceptor cell OS length constant (10-12). This process of OS disc renewal is circadian 
and occurs daily in mammals. 
Each photoreceptor cell has a specific role for the type and amount of light that leads to 
its signaling response. Rods are highly sensitive photoreceptors that respond to single photons of 
light. Therefore, they are active in dim-light settings and allow for night-time vision. Rods have a 
response range of three orders of magnitude, up to 10,000 photons per second (mesopic vision), 
at which point they saturate (13). When the rods saturate, the cones begin to respond (photopic 
vision). By shifting their operating curves, cones take the human eye out to 10 billion photons 
per second (as could be seen during the noon sun on freshly fallen snow at altitude). There are 
different variations of cone cells, each responsible for sensing different wavelengths of light, and 
therefore allowing for day-time, color vision. In humans, there are three types of cone cells: the 
S-cones, L-cones, and M-cones. The macula, a central region of the retina, is enriched in cone 
cells, causing the cones to be responsible for the central visual field while the rod cells comprise 
the majority of the peripheral visual field (13-14). 
Using the photoreceptor cells’ sensitivity to light, the retina takes responsibility for two 
major functions of vision. One, it transduces light into neural signals; and secondly, these neural 
signals are then transmitted to the brain in a manner in which the brain can recognize and 
decipher the visual image. Retinal circuits transform patterns of light and darkness on the 
photoreceptor mosaic of the retina, and these patterns lead to repetitive discharges from a two-
dimensional array of ganglion cells to the brain. Over the past years, progress has been made in 
understanding the mechanisms of neurocircuitry and phototransduction in the retina. No 
feedback from the brain to the retinal cells occurs during the visual process, and therefore the 
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phototransduction signaling cascade in the photoreceptor rods and cones is of high importance to 
produce correct visual images. 
 
PHOTOTRANSDUCTION CASCADE 
 The photoreceptor cells contain opsins in the OS discs, which are light-sensitive pigments 
that photoactivate after light exposure. Each OS disc contains several million opsin molecules 
(15). These photoexcited opsins then stimulate the cell membrane of the photoreceptors to trigger 
signals that are transmitted through the inner retina, to the optic nerve, and on to the brain. In the 
dark, there is a circulating current that flows from the IS to the OS of the photoreceptor cell. 
After light exposure, the OS undergoes a process, called the phototransduction cascade, which 
interrupts this cell current. This cascade occurs on the stacks of disc membranes and leads to 
altered cyclic guanosine monophosphate (cGMP) levels in the photoreceptor OS. The change in 
cGMP levels in the photoreceptor transmits the light response signal from the OS discs to the 
plasma membrane of the photoreceptor cell (16). This process is carefully regulated by various 
molecules, each of which is responsible for the activation, deactivation, and adaptation of the 
phototransduction cascade in the photoreceptor cell. 
The phototransduction cascade is activated when light is absorbed by a molecule in the 
OS of the photoreceptor, called rhodopsin (RHO). RHO is a seven-loop transmembrane G-
protein coupled receptor that contains a protonated Schiff base with a lysine side chain. This 
lysine side chain is covalently linked to an 11-cis chromophore (17-18). A photochemical event 
occurs after light sensation to the photoreceptor cells, which causes the geometrical 
photoisomerization of the pigment 11-cis retinylidene chromophore into an all-trans 
configuration (19). After light stimulation, this pigment can no longer be photoactivated. 
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Therefore, a mechanism exists within the retina to regenerate these light-sensing pigments. The 
all-trans retinylidene is isomerized back into the 11-cis configuration, to create a pigment that 
can be photoactivated by light (19-20). This entire process is known as the visual cycle (Figure 
3) 
 
 
Figure 3. The Visual Cycle. Vision begins when light (hν) causes the photoisomerization of the 
11-cis retinylidene chromophore of ground-state RHO. Subsequently, the Schiff base linkage 
loses a proton enabling RHO to activate G proteins (i). After remaining active for a short period 
of time, the isomerized chromophore is released via hydrolysis, generating free all-trans retinal 
and opsin (ii). The all-trans retinal is enzymatically reduced (iii) and the resultant all-trans 
retinol is exported from the rod OS to the RPE. All-trans retinol is metabolized by LRAT to 
produce all-trans retinyl esters (iv), which can be either stored in retinosomes in the RPE or 
further processed. RPE65 is the key enzyme that catalyzes the conversion of all-trans retinyl 
esters to 11-cis retinol (v). 11-cis retinol is enzymatically reduced to 11-cis retinal (vi), which is 
then transported back to the photoreceptor OS where it recombines with opsin to form ground-
state RHO (vii). Continuous operation of this cycle is what sustains vision under conditions 
where rods are primarily active. RHO, rhodopsin; OS, outer segment; RPE, retinal pigment 
epithelium; LRAT, lecithin:retinol acyltransferase; RPE65, retinal pigment epithelial protein 65 
kilodalton (Adapted from 19). 
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In the vertebrate, the Schiff base link between the chromophore and opsin is hydrolyzed, 
which allows for free all-trans retinal to be released. This is a process known as bleaching (19). 
This all-trans retinal is then reduced within the photoreceptor cell by NAD(P)H-dependent 
retinol dehydrogenases (RDHs) to yield all-trans retinol, otherwise known as vitamin A. Vitamin 
A is transferred into the RPE cell layer to be esterified by lecithin:retinol acyltransferase (LRAT) 
for storage (19). Within the RPE cells, stored all-trans retinyl esters are isomerized to 11-cis 
retinol by retinal pigment epithelial 65 kilodalton (RPE65) protein. This occurs in a complex 
enzymatic reaction that involves the simultaneous hydrolysis of the ester moiety. The 11-cis 
retinol is then oxidized to 11-cis retinal. 11-cis retinal then passes out of the RPE and into the OS 
of the photoreceptor cell to bind to opsin and make the RHO molecule.  
Light causes this RHO molecule to undergo a conformational change to an activated 
state, called metarhodopsin II (Rh*). Rh* next activates hundreds of transducin molecules 
(Gtαβγ). Gtαβγ are heterotrimeric G-proteins that act by exchanging guanosine diphosphate (GDP) 
for guanosine triphosphate (GTP) (21). This activation by Rh* causes GTP to bind to the Gtα 
subunit of Gtαβγ, and this Gtα-GTP then dissociates from the Gtβγ portions of Gtαβγ. After 
dissociation, the Gtα-GTP binds to the inhibitory γ subunits of cyclic guanosine monophosphate 
(cGMP)-phosphodiesterase 6 (PDE6) (22).  
PDE6 is a heterotetrameric protein consisting of a catalytic α-subunit, a catalytic β-
subunit, and two inhibitory γ-subunits in the rod photoreceptor cell. In the cone cell, PDE6 
consists of a catalytic dimer that contains two identical α’ subunits, rather than the α and β 
subunits found in the rod cell. Additionally, the γ’ inhibitory subunits of the cone PDE6 differ 
slightly in size and amino acid composition from the rod γ inhibitory PDE6 subunits (16). PDE6 
is highly important in the phototransduction cascade, as it is the primary regulator of cytoplasmic 
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cGMP concentration in the photoreceptor cells. In the dark, PDE6 is in an inactive form, with the 
γ inhibitory subunits bound (PDE6αβγ), and cGMP levels within the photoreceptor cell OS are 
high (several micromolars) (16). This allows for cGMP-gated Na
+
/Ca
2+
 ion (CNG) channels 
within the plasma membrane to remain open, allowing a current to circulate through the 
photoreceptor cell. 
 After light stimulation of the phototransduction cascade, the binding of Gtα-GTP on the 
γ-subunits of PDE6 removes the inhibition on the catalytic α- and β-subunits of PDE6 (21-23). 
The activated PDE6 hydrolyzes cGMP, breaking it down and reducing its concentration within 
the photoreceptor cell (24). This light-activated PDE is approximately 300 times more active 
than in its basal state, rapidly breaking down the cyclic nucleotide levels (25). The rapid 
reduction of cGMP within the photoreceptor cell after light stimulation of the phototransduction 
cascade causes the CNG channels located on the plasma membrane to close. Therefore, the 
levels of Na
+
 and Ca
2+
 into the cytoplasm are reduced, causing the rod cell to become 
hyperpolarized. Hyperpolarization of the rod cell causes it to decrease glutamate at its synaptic 
terminal to signal to the other neuronal cells of the retinal and on to the optic nerve and the brain. 
After light stimulation, the phototransduction cascade has to undergo deactivation in 
order to return cGMP to its basal levels. The photoexcited Rh* is inactivated by the 
phosphorylation of threonine and serine residues at its carboxyl tail by a rhodopsin-specific 
kinase called G protein-dependent receptor kinase I (GRK1) (10). This phosphorylated rhodospin 
(Rh*-P) has more efficient binding toward a molecule called arrestin (Arr; also called S-antigen), 
rather than Gtα. Arr acts on the Rh*-P by inhibiting the removal of the phosphate groups (26). 
This rapidly reduces the amount of dephosphorylated, active Rh* available for the activation of 
Gtα and the rest of the phototransduction cascade.  
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Additionally, Gtα has intrinsic GTPase activity to inactivate itself after its binding to the γ 
inhibitory subunits of PDE6 (25). The PDE6αβ catalytic subunits re-associate with the two 
PDE6γ subunits for inactivation of the PDE6 complex while retinal guanylate cyclases (Ret GC-
1 and Ret GC-2) become activated and reproduce cGMP in the photoreceptor cell (10). The 
return of the basal cGMP concentration in the photoreceptor cell re-opens the CNG channels. 
The deactivation process is now complete. Activation of the phototransduction cascade starts 
again when Rh*-P-Arr binds to 11-cis retinal which releases the molecule from Arr. The Rh*-P 
is then dephosphorylated by phosphatase 2A and the light/dark activation/deactivation cycle can 
continue within the photoreceptor cell (Figure 4). 
 
 
Figure 4. Phototransduction in vertebrate rods. Light converts rhodopsin into an active form, 
Rh∗, which activates heterotrimeric Gt by GTP-GDP exchange. Active Gtα (Gtα∗) binds to and 
activates phosphodiesterase (PDE), which hydrolyzes cyclic GMP (cGMP) to GMP, thereby 
closing the cyclic-nucleotide-gated (CNG) channels that are open in darkness. hν, photon; Rh∗-P, 
phosphorylated Rh∗, which retains partial Rh∗ activity; Rh∗-P-Arr, phosphorylated Rh∗ with 
arrestin bound, rendered fully inactive. Red lines ending in a small bar indicate negative-
feedback (inhibitory) pathways via Ca
2+
. The inhibition by Ca
2+
 on the cGMP gating of the CNG 
channel is via a Ca
2+
-binding protein that may be calmodulin. Inset: schematic diagram of the 
ciliary rod photoreceptor, with a light-sensitive outer segment formed from a highly expanded 
cilium (Adapted from 27).  
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In addition to the activation and deactivation of the phototransduction cascade, there is 
also the photoreceptor cell adaptation to constant light stimulus. As previously mentioned, light 
stimulation of the phototransduction cascade leads to the closure of the CNG channels in the 
photoreceptor OS. This induces a decline in Ca
2+
 influx into the cell. Intracellular Ca
2+
 levels act 
to inhibit the guanylate cyclases (Ret GC-1 and Ret GC-2). Therefore, Ret GC-1 and Ret GC-2 
are activated when light stimulates the phototransduction cascade and Ca
2+
 levels decrease 
within the cell (28-30). This occurs through the stimulation of Ret GC-1 and Ret GC-2 by the 
guanylate cyclase activating proteins (GCAP-1/p-20 and GCAP-2/p24). These guanylate 
cyclases work to form more cGMP to counteract the reduction in cGMP by PDE6 after the 
activation of the phototransduction cascade.  
Additionally, a molecule called recoverin then mediates the Ca
2+
 sensitivity of GRK1 
phosphorylation of Rh*. Thus, prolonged light leads to a reduction in Ca
2+
 levels and induces 
GRK1 activity by reducing recoverin’s inhibition of GRK1. Furthermore, the CNG channel, 
responsible for the ionic current of the photoresponse, binds a molecule called calmodulin at 
high levels of Ca
2+
, and prolonged light reduces calmodulin binding and leads to a decline in the 
channel affinity for cGMP (31). This causes the channel to re-open at lower levels of cGMP than 
it would in dark conditions. 
Lastly, light adaptation leads to a greater inhibition of the PDE6 enzyme to allow for a 
rapid reduction in the hydrolysis of cGMP. Ca
2+
-sensitive members of the protein kinase C 
(PKC) family phosphorylate the two PDE6γ subunits. This phosphorylation site is blocked while 
the γ subunits are attached to PDE6αβ, but light activation of the phototransduction cascade 
allows for Gtα-GTP to release the γ inhibitory subunits from the PDE6αβ complex. After GTP 
hydrolysis, free PDE6γ are then phosphorylated by members of the PKC family at threonine 35, 
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which allows them to re-bind to PDE6αβ and lead to a greater inhibition of the catalytic activity 
of PDE6. 
As would be expected, alterations in the activity of the phototransduction cascade, such 
as changes affecting the renewal and shedding of the photoreceptor OS, visual transduction, 
and/or retinol metabolism have a great impact on the health of the retina. Mutations within any 
of the molecules responsible for these visual processes cause several types of retinal and RPE 
degenerative diseases. The majority of retinal degenerations are caused by gene defects, leading 
to reduced protein levels or incorrect protein functions (5, 10, 32). For example, the inability of 
the RPE to phagocytose the photoreceptor OS causes a form of autosomal recessive retinitis 
pigmentosa (arRP) (10, 33). arRP, and other retinal degenerative diseases, are a common 
healthcare issue within the world. 
 
PART II: RETINAL DEGENERATION 
IMPACT 
Sadly, retinal degeneration is a common occurrence in the world. The loss of sight affects 
approximately 3.4 million people in the U.S.A. alone and is expected to increase over the years 
(34). Visual impairment ranks only behind arthritis and heart disease with respect to disease 
impact on function in the elderly. In fact, visual loss is often considered by patients to be their 
dominant health issue, even in the presence of other chronic disabling disorders (35). Patients 
exhibit a loss of quality of life, as they need assistance in daily tasks such as walking, reading, or 
driving.  
There is great genetic and allelic heterogeneity of the various retinal dystrophies. These 
diseases have been classified using age of onset, electrophysiological and psychophysical 
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studies. However, these classifications can be ambiguous as there are similar clinical 
presentations in retinal degenerations arising from different genetic mechanisms. For instance, 
RP can be caused by both mutations within members of the phototransduction cascade, such as 
RHO or PDE6, and also by mutations within rod OS membrane proteins, such as peripherin (36-
37). Additionally, different mutant alleles at the same locus can cause varying clinical 
presentations of disease. For example, mutations within the β subunit of PDE6 can cause two 
different retinal degenerative diseases: either congenital stationary night blindness or RP (36-37). 
Currently, the most precise method of classification is based on the specific molecular genetic 
defect, and genetic testing is becoming a common practice used by clinicians to complement 
their clinical diagnosis. 
 
AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA 
As mentioned, photoreceptor neurodegenerative diseases have large impacts on both 
patients and society. Sadly, they have no cure. One of the most devastating photoreceptor 
degenerative diseases is RP, which is the focus of this work. RP is the most common cause of 
hereditary blindness worldwide, affecting approximately 1:3000 people (5, 38-41). There are 
various forms of RP, including autosomal dominant (15-20% of cases), autosomal recessive (20-
25% of cases), and X-linked (10-15%).  The remaining 40-55% of cases is currently of 
unclassified inheritance (Figure 5; 42-43). These unclassified RP patients are usually due to the 
absence of family histories, and are denoted as simplex RP. The majority of simplex RP cases 
are believed to be autosomal recessive (43). Autosomal dominant forms of RP are usually the 
mildest, with onset that can occur as late as 50 years of age. Autosomal recessive, on the other 
hand, are more severe and disease onset typically occurs during the first decade of life (44). 
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Additionally, RP can be secondary in etiology and is involved in more than 30 disease 
syndromes. Most forms of syndromic RP present with extraocular abnormalities and are 
autosomal recessive disorders, such as Usher and Bardet-Biedl syndromes (43). 
 
 
Figure 5. Genes and their relative contribution to retinitis pigmentosa. Causal genes and 
their contributions to autosomal-recessive disease (arRP), including Usher's and Bardet-Biedl 
syndromes. About 40% of cases are due to genes that are as yet undiscovered. These cases are 
represented by three pie slices named unknown non-syndromic retinitis pigmentosa 30%; 
unknown BBS 3%; and part of MASS1, USH2B, and unknown 10%. The figure does not include 
Leber congenital amaurosis, cone-rod dystrophy, macular degeneration, or cases with maternal 
inheritance (eg, Kearns-Sayre syndrome). For some genes, only one or a few families have been 
reported with mutations; in these cases, the gene frequency was arbitrarily set at 1% (Adapted 
from 45). 
 
Genetically, most forms of RP are monogenic, although there have been cases of digenic-
diallelic and digenic-triallelic inheritances. Due to RP being both locus heterogenous and 
phenotypically heterogenous, mutations in no single gene are known to cause more than 10% of 
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cases of RP (43). In 2013, there are 45 genes mapped that cause non-syndromic forms of RP, 
although there is likely to be many more genes responsible for this disease as approximately 200 
more genes have already been identified that are involved in retinal disease (46). 
In RP, the progressive atrophy of the rod photoreceptor cells leads to the secondary death 
of the cones. Affected individuals will present with night blindness, tunnel vision, and eventual 
loss of central vision as the cone cells degenerate. This photoreceptor cell death has been thought 
to result from a caspase-dependent apoptotic mechanism, as was seen in animal models of retinal 
dystrophies (47-48). However, there have been recent studies suggesting that other disease 
pathways, such as calpain-mediated cell death or proteasome activity, may be responsible for the 
degeneration of the photoreceptor cells (10, 49-50). Although it remains to be elucidated which 
death mechanism leads to the loss of the photoreceptors, RP can be classified into three stages of 
clinical disease.  
In stage I of RP, patients present with night blindness. Most patients ignore this 
symptom, and typically will not recognize the disease phenotype until the teenage years, when 
they attend evening events (44). There are no visual defects present in the daylight, and patients 
have normal life activities. Only the electroretinogram (ERG), a clinical test that measures the 
electrical response of the retinal cells to flashes of varying light intensities, will display a loss of 
visual response at this time (44). Therefore, at the early disease stage most patients will not be 
clinically diagnosed with RP. 
In the mid-stage of RP, patients will have difficulty performing most nighttime activities, 
such as driving, and will become aware of a loss of their peripheral visual field even in the 
daylight. Additionally, patients may become photophobic, especially in regards to diffuse light, 
such as cloudy weather days (44). This causes difficulty reading and performing daily activities. 
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At this stage, patients notice the disease phenotype, visit a clinician, and are typically diagnosed 
with RP.  
At the clinic, fundus examination will display the presence of bone-spicule shaped 
pigment deposits in the mid-periphery of the retina, along with retinal pigment epithelial atrophy. 
Narrowing of the retinal vessels is also apparent at this time. ERG examination will show an 
attenuated visual response in the cone cells, and a complete loss of visual response under 
scotopic, dark-adapted conditions (Figure 6; 44). This condition reflects the loss of the majority 
of the rod photoreceptor cells.  
In the final stage of RP, the clinical presentations that occur in the mid-stage of the 
disease will worsen until the patients have lost their ability to perform daily tasks on their own, 
without assistance from others. They will then continue to progress until the loss of their central 
visual field, rendering them blind. This disease not only affects the patient and their loved ones, 
but society as a whole. RP patients have progressively declining vision that inevitably leads to 
blindness, and society is faced with the high costs of caring for each of these visually 
handicapped persons for the remainder of their lives. 
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Figure 6. Retinitis pigmentosa caused by a mutation in the alpha subunit of 
phosphodiesterase 6. Color montage fundus photograph of a normal retina (A) and a color 
montage fundus photograph of a human patient with mutations in PDE6A showing extensive 
peripheral intraretinal pigment migration (B). Representative electroretinogram (ERG) 
recordings from compound heterozygous II-4, a patient with mutations in PDE6A compared with 
representative ERG recordings from a normal control patient (C). Shown from left to right are a 
rod-isolated response in the first column, the dark-adapted maximal response in the second 
column, flickering (30 Hz) stimuli in the third column, and the light-adapted cone response to 
single flash (1 Hz) in the fourth column. a- and b-waves are identified using ISCEV techniques. 
Note the barely detectable rod-isolated response (II-4) compared to the normal control (Adapted 
from 51). 
 
RP is arguably one of the best models for studying neurodegenerative diseases, for three 
main reasons. First of all, the basic pathogenic process in RP, that of rod cell atrophy leading to a 
secondary, non-autonomous death of the cone cells, is generalizable to other forms of retinal 
degenerative diseases, such as age-related macular degeneration (AMD) or even normal aging. 
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Secondly, multiple mouse and dog models now exist for mutations in PDE6 leading to RP, 
which is the third most common cause of autosomal recessive RP (45). Third, unlike mouse 
models of EYS (52) or ABCA4 (53), common photoreceptor degenerative diseases in which the 
mouse model does not mimic human disease, these mouse models with loss of function of PDE6 
mimic the human phenotype. 
Human RP patients due to a deficiency in PDE6 have rod photoreceptor cell loss that is a 
direct consequence of the rod-specific function of PDE6 during the phototransduction cascade. 
Cone cell loss, on the other hand, is due to secondary, non-cell-autonomous effects. These are 
uncertain, but may be due to decreased levels of survival factors produced by healthy rods and/or 
increased levels of toxic factors produced by diseased rods. These are likely scenarios since rod 
cells make up 97% of the photoreceptors with cones being only 3% of the cells. Scientists and 
clinicians have begun searching for therapeutic agents that will be effective in slowing the 
photoreceptor cell death, and/or curing the causative genetic defect. 
 
PART III: THERAPEUTIC OPTIONS 
BRIEF OVERVIEW OF CURRENT EXPERIMENTAL THERAPIES 
Patients with RP are not curable, and at this time there are no standard treatments in 
clinical practice to stop the progression of photoreceptor degeneration and loss of vision. 
However, there are several methods being studied to try to slow down the rate of degeneration 
and allow for patients to extend the time in which they are able to obtain their central visual 
field. One method used for patients with RP is to provide dark sunglasses for use outdoors, in 
order to block the amount of light to the photoreceptor cells (44). Since a majority of RP cases 
are caused by mutations within the phototransduction cascade, which is activated by light, this 
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decreases the effects of these mutations by reducing the light stimuli. Additionally, yellow-
orange glasses block photophobic effects for patients and are provided by some clinicians (44). 
However, these methods for protecting the photoreceptor cells cannot provide a cure for the 
disease, and various other therapeutic options are being tested for RP patients. 
A main study that was conducted examined the effects of vitaminotherapy for RP. 
Vitamin A was hypothesized to protect the photoreceptor cells by a trophic effect, and vitamin E 
through anti-oxidant protective effects (44, 54). Studies have shown that long-term (5-12 year) 
supplementation of 15,000 units of vitamin A per day was able to slightly slow down the loss of 
visual function as noted by the cone ERG b-wave amplitude in RP patients. However, 400 units 
of vitamin E per day had adverse effects in RP patients (44, 54). Since vitamin A is stored in the 
body, patients taking vitamin A supplementation at high doses should be monitored as well for 
potential toxicity, and clinicians debate the usefulness of this treatment.  
Another method is to give RP patients 1200mg/day of docosahexanoic acid (DHA) 
supplements in addition to the vitamin A supplementation, which showed an initial slowing of 
the disease in trials, but one which did not last in patients beyond two years of follow-up (44).  
Additionally, patients with the ABCA4 gene mutation that leads to Stargardt’s disease, another 
retinal degenerative disease, have adverse effects after vitamin A supplementation (44). These 
are the most promising treatment options at this time for RP, and whether or not they will have 
any significant slowing of retinal degeneration is debatable.  
Another option is to use pharmacological treatments if the mechanism of degeneration is 
known for the patient. Animal studies have examined the use of calcium channel blockers to 
slow down RP progression. This is thought to be effective since increases in cGMP leads to a 
consistent opening of the CNG channels and alters the ion current to cause photoreceptor cell 
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death. However, these animal studies have shown limited success (44). One of the more 
promising pharmacological treatments analyzed the effects of 9-cis retinal in mouse models of 
Leber congenital amaurosis (LCA), an early-onset blinding disorder. LCA patients have 
mutations in RPE65, which is the isomerase that acts in the visual cycle for the conversion of all-
trans retinyl esters to 11-cis retinal for binding to opsin. 9-cis retinal is believed to be able to 
bind opsin and create a modified form of rhodopsin that can be activated by light and function in 
the phototransduction cascade. Delivery of 9-cis retinal to the Rpe65
-/-
 mouse model of LCA has 
restored rod cell activity, however further studies are needed to determine the extent of rescue for 
this pharmacological treatment (44).  
Additional pharmacological therapies include treating mouse models of Stargardt disease, 
a blinding disorder thought to involve the accumulation of bisretinoid lipofuscin in the RPE, with 
visual cycle inhibitors. These studies have also shown some slowing in the accumulation of 
lipofuscin, thought to lead to the RPE-related disease phenotype (44). As more genetic mutations 
and mechanisms of retinal degenerative disease are known, pharmacological treatments can 
become more targeted and better developed. These agents are promising, and may have the 
potential to be useful therapeutic options to slow the progression retinal degenerative diseases, 
such as RP. 
Another treatment method is to use growth factors to provide neuroprotection to the 
photoreceptor cells and therefore limit photoreceptor degeneration. Animal models have shown 
some efficacy using a variety of growth factors, such as ciliary neurotrophic factor, brain-derived 
neurotrophic factor, and glial-derived neurotrophic growth factor (44). However, these factors 
have to be delivered in situ to the animal, due to the short half-life of the growth factors. Several 
strategies are being developed for this delivery, such as gene transfer and the use of encapsulated 
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cells placed into the vitreous cavity (44). However, these factors can have side effects that 
include cataract, which would lead to a loss of vision. The use of ciliary neurotrophic factors is 
currently in Phase I of human clinical trials for patients with RP; however it has been shown to 
decrease the ERG response in several animal models of retinal degeneration, suggesting a 
potential undesirable effect of the growth factor or delivery system (44). 
Besides treatments that may only slow the progression of retinal degeneration, scientists 
are also working on methods to replace the already degenerated photoreceptor cells. One way in 
which to achieve this goal is to use retinal prosthetic devices. These devices incorporate 
microphotodiode arrays that are able to capture light and stimulate the retina. They can be 
incorporated into the eye to act in the phototransduction cascade, or they can be incorporated in 
sites responsible for later stages of the visual signaling cascade. These sites include directly 
stimulating the optic nerve or the visual cortex of the brain. One of these early retinal prothestic 
devices has been approved by the Federal Drug Administration and is shown to be tolerated by 
the human patients after implantation (44). However, they are not yet a standard therapy for RP, 
but further studies and improvements in the prosthetics make them a viable option. 
Another method to replace the degenerated photoreceptor cells is to transplant cells from 
fetal or adult retina into humans. In current published cases, cell transplantation studies using 
photoreceptors allowed survival of the transplanted cells within the host diseased retinas, but 
they were unable to arrange and organize themselves to provide proper structure and synaptic 
connections (44). The ideal therapy will be the use of stem cells, whether embryonic or patient-
derived induced pluripotent stem cells, to create stocks of cells or tissues for transplantation into 
patients with RP.  
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Promising results from cell transplantation experiments have occurred in animal models 
of retinal degenerative diseases. RPE grafts have been able to rescue both the Royal College of 
Surgeons (RCS) rats and the Rpe65
-/- 
mouse model (44, 55). However, these therapies are still 
undergoing investigation and more research must be done before one can create a purified cell or 
tissue of interest in vitro that will be able to make all the necessary synaptic connections in vivo 
after transplantation.  
 
GENE THERAPY 
Gene therapy has become the key therapeutic tool for treating blindness resulting from 
retinal degenerative diseases. Current technology has allowed for the elucidation of disease-
causing alleles and specific genetic defects, which gives scientists the ability to create a gene 
therapy vector that can target these specific genes of interest. There are many vectors that can be 
utilized for gene therapy, including both viral and non-viral vectors. Most often, viral vectors are 
used; although small molecules are now being created that have the capabilities to efficiently 
transfect the cells of the retina. 
The first viral vector to be popular for use in gene therapy was the lentivirus. Lentiviruses 
were of interest due to the fact that they could hold approximately 9 kilobases (kb) of 
deoxyribonucleic acid (DNA), and also infect non-dividing cells, such as the photoreceptor cells 
(54). Lentiviral vectors utilize the human immunodeficiency virus (HIV) genome, which codes 
for three structural (Gag, Pol, and Env) and six regulatory (Vif, Vpr, Vpu, Tat, Rev, and Nef) 
proteins. At first, the whole HIV genome, for the exception of the packaging signal and viral env 
gene, was used as a packaging construct to deliver the gene of interest. However, it was still 
possible that the virus could become replication-competent once again, after three 
22 
 
 
recombinations, which would be a potential safety hazard for clinical usage. Second and third 
generation lentiviruses are being developed, in which various regulatory proteins are deleted 
from the packaging construct (56). At this time, only the in vivo potential pathogenicity of the 
HIV-1 based viruses, such as lentiviruses, can be estimated by in vitro tests, and many more 
technical improvements and experimental studies of both efficiency and safety need be 
completed before their clinical use. 
 
ADENO-ASSOCIATED VIRAL VECTORS 
Current experiments utilize an adeno-associated virus (AAV) as the new standard for 
retinal gene therapy (57-58). AAV is a non-enveloped, icosahedral-shaped member of the 
parvoviridae family; therefore it is a small virus with a virion approximately 25nm in diameter 
composed entirely of protein and DNA (59-60). This means that AAV vectors are only capable 
of packaging approximately 4.7 kb of DNA (61). Thus, both the gene of interest and the 
promoter must fit this space requirement, making it a limiting factor of using AAV.  
The AAV2 genome is the most widely studied, and is composed of linear, single-stranded 
DNA containing 4679 nucleotides (59-60, 62). The AAV genome is composed of 3 open reading 
frames (ORFs) flanked by inverted terminal repeat (ITR) sequences that function as the viral 
origin of replication (ori) and packaging signal (60). AAV2 contains one ORF with two genes 
that encode four non-structural replication proteins (Rep40, Rep52, Rep68, and Rep78) and 
another ORF with three 60-mer capsid proteins (VP1, VP2, and VP3), along with the third ORF 
containing an assembly-activating protein that is flanked on each side by 145 base-pair ITRs 
(Figure 7; 59-60, 62-64). The two larger replication proteins, Rep68 and Rep78, play a role in 
most aspects of the AAV2 life cycle, such as transcription, replication of the viral DNA, and site-
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specific integration into human chromosome 19. The two smaller replication proteins are used 
for packaging of the DNA into the viral capsid (59, 65). The three capsid proteins utilize 
different translational start sites, even though they come from the same ORF.  
 
 
Figure 7. AAV2 genome organization. The horizontal arrows indicate the three transcriptional 
promoters (p5, p19, and p40). The black solid lines represent the transcripts and the introns are 
shown by the angled lines. The polyadenylation signal is common to all transcripts. The first 
open reading frame encodes the four replication proteins arising from the p5 and p19 promoters 
and alternative splicing. The second open reading frame utilizes the p40 promoter and encodes 
the three capsid proteins from two transcripts. VP1 is initiated from the first capsid transcript and 
VP2 and VP3 are initiated at two different codon sites from the second capsid transcript (59). 
 
There are eleven known naturally occuring serotypes for AAV, and over 100 variants 
(60). The capsid proteins can be found in different configurations for the various AAV serotypes, 
AAV1-9, but it is believed that they are found in a ratio of 1:1:10 VP1:VP2:VP3 (59, 66-67). 
These AAV capsid proteins determine its tropism (the ability to transduce specific cell types), 
allowing for both cell surface receptor binding and the entry into the host cell nucleus (60). The 
mechanism by which AAV enters a host cell is via phagocytosis by receptor-mediated 
endocytosis (59, 68). There has been evidence supporting the use of both clathrin-coated pits and 
clathrin-independent carriers/glycosylphosphatidylinositol-anchored protein-enriched endosomal 
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compartments for this process (60). The methods of cell entry for each AAV serotype remains to 
be studied. 
After entry into the host cell, the capsid then leaves the endosome and enters the nucleus. 
There has been evidence supporting both uncoating before nuclear entry, and uncoating after 
nuclear entry, and the exact timing of the uncoating of the capsid is yet to be proven (60). 
However, the localization to the host cell nucleus occurs via capsid protein VP1, which contains 
a phospholipase domain that allows for the escape from the endosome (59, 69). The N-termini of 
capsid proteins VP1 and VP2, which contain nuclear localization signals, then direct the capsid 
to the host cell nucleus (59, 70). The genome is released in the nucleus by the capsids and 
converted to double-stranded DNA by the replication proteins and host cellular DNA synthesis 
machinery (59-60, 71).  
Without the presence of a helper virus, AAV enters a latent life-cycle and the DNA is 
retained in a circular episomal form within the nucleus, or else integrated into the human 
chromosome 19, at a specific site termed AAVS1 (59, 72-74). Because AAV serotypes contain 
variations in the capsid proteins, each serotype has varying tropism for different target cells and 
tissues. Thus, recombinant AAV vectors used in gene therapy have to be chosen for their ability 
to efficiently and effectively transduce the cell-type of interest. 
Between 1950 and 1990, AAV serotypes 1-6 were isolated and these were molecularly 
cloned through the following 10 years (67). These new natural AAV serotypes were able to 
provide better tropism and transduction efficiency in murine models compared to AAV2. For 
example, AAV1 was discovered to more effectively transduce muscle cells compared to AAV2, 
and AAV5 to more effectively transduce the central nervous system in comparison to AAV2. 
After this discovery, the University of Pennsylvania isolated latent AAV from non-human 
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primates and human tissues using PCR and identified over 120 novel AAV isolates, four of 
which were uncharacterized (67). Three new serotype vectors, AAV7-9, provided even greater 
transgene expression levels in tissues such as the liver, muscle and retina. These tissues are 
highly targeted by therapeutic agents to treat disease, making these AAV serotypes exciting for 
the possibility of delivering gene therapy vectors to these tissues that were previously difficult 
for clinicians and researchers to treat with therapeutic agents. 
The recombinant forms of AAV used as a packaging vector for gene therapy has its viral 
components, the replication and capsid proteins, removed from the final gene therapy virus. This 
makes the AAV non-pathogenic and potentially safe for human clinical trials. The ITRs that 
flank the AAV genome are the only cis-acting elements in the AAV that are necessary for the 
genome replication, integration, and packaging of the capsid (59). Thus, the replication and 
capsid proteins flanked by the ITR sites are replaced with the promoter and gene of interest for 
gene therapy. The replication and capsid proteins are then expressed in trans in a different 
plasmid that lacks the ITRs, blocking the formation of a viral AAV particle after delivery (59). 
The recombinant AAV vector is able to transduce both dividing and non-dividing cells with 
stable transgene expression without the presence of a helper virus in post-mitotic tissue (60). 
These features make recombinant AAV an excellent tool for gene therapy studies for human 
diseases. 
However, science did not stop developing the AAV gene therapy vector system at this 
point. These recombinant AAV particles have been made more efficient using various 
technological advances. One of these is the creation of self-complementary (sc) AAV vectors. In 
scAAV vectors, the terminal resolution site of one ITR is deleted, preventing the initiation of 
replication at this end (59, 75). This creates a single-stranded, inverted repeat genome with one 
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wild-type ITR at one end and a mutated ITR in the middle. This allows for the vector genome to 
fold after uncoating and creates a double-stranded, or self-complementary, genome (Figure 8).  
These scAAVs, therefore, do not need the host cell DNA synthesis machinery to convert 
single-stranded DNA to double-stranded DNA before transcription and translation; they are 
incorporated with their DNA in the double-stranded form. There is a more rapid onset of gene 
expression using scAAV vectors in comparison to recombinant AAV vectors, due to this skipped 
step in DNA synthesis, and these scAAV vectors have been able to transduce cell types that 
previously did not express transgenes using the recombinant, single-stranded AAV vectors (59). 
However, these vectors are half the size of the recombinant AAVs, making them more limiting 
than recombinant AAV vectors due to DNA packaging constraints. 
 
 
Figure 8. AAV replication cycles. Replication cycles for the generation of (left) single-stranded 
genomes and (right) self-complementary genomes (59). 
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Scientists found another method in which to enhance the recombinant AAV vectors. 
They created hybrid AAVs, in a process called “pseudotyping,” to create vectors that target 
specific cell types with higher efficiency. At the time, research had found AAV gene therapy 
viruses to be limited in regards to certain cells of interest. For example, AAV2 vectors were the 
most commonly studied, and these vectors were used to efficiently transduce RPE cells in large 
animal models for several years. This made them an attractive therapeutic agent because they 
could potentially have a long-term effect after a single administration of the vector into human 
patients (76). Although AAV2 has been effective for transduction of the RPE cells, it was not 
shown to have a long-lasting effect on the photoreceptor cells (77-78).  
Therefore, pseudotyping became a method to create AAV vectors that would more 
efficiently transduce the photoreceptor cells and other cell types not efficiently targeted by 
AAV2. Pseudotyping uses the recombinant AAV2 plasmid (with the ITRs from AAV2) and 
packages it into a capsid derived from a different AAV serotype. This places the AAV2 
replication sequence downstream of the p19 promoter with the respective replication sequence of 
another serotype added after the promoter sequence (59, 79). These AAV vectors are named 
using the serotype 2 replication proteins and the number from the AAV serotype capsid proteins. 
For example, a wild-type AAV2 vector would be typically written as “AAV2/2,” while the AAV 
serotype 8 gene therapy vector is written as “AAV2/8.”  
This pseudotyping process allowed for advantages in the usage and efficiency of AAVs 
in regards to gene therapy. For instance, the same vector genome, from AAV2, is packaged into 
the different AAV serotype capsids. Thus, the only difference between the pseudotyped AAV 
vectors is their capsid proteins. This allowed for research to analyze each AAV serotype in vivo 
and examine its transgene expression efficiency and cellular tropism (59, 79-80). It was 
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discovered that AAV2/2, the commonly used AAV serotype, allowed for a gradual increase in 
transgene expression over time, to stabilize at approximately 2-4 months post-injection. In 
contrast, AAV2/1 or AAV2/5 vectors were able to display the onset of transgene expression by 
3-4 days post-injection (76).  
Besides the earlier onset of gene expression, the different AAV serotypes and 
pseudotyped vectors were found to have varying tropism, and more efficiently transduce specific 
retinal cells. For instance, AAV2/4 is able to more efficiently target the RPE cells than AAV2/2, 
AAV2/5 efficiently targets both RPE and photoreceptors, and AAV2/8 has been found to be the 
most efficient and targets the RPE cells and the rest of the cells of the neural retina 
(photoreceptors, ganglion cells, and the inner nuclear layer) (58, 76, 81-83). Therefore, 
researchers can choose the AAV gene therapy vector based on the cell that they are interested in 
targeting with their transgene, and how fast they would like the onset of transgene expression to 
occur in this cell. 
After pseudotyping, more technological advances in AAV gene therapy vectors were 
made to enhance their usage as gene therapy viruses. Epidermal growth factor receptor protein 
tyrosine kinase (EGFR-PTK) signaling impairs the nuclear transport of AAV2 vectors and 
decreases the virus transduction (84). The capsid proteins contain tyrosine amino acids that 
undergo phosphorylation into phenylalanine when it is detected by the host cell, by EGFR-PTK, 
and this communicates to the host cell to degrade this foreign protein. It was hypothesized that 
site-directed mutagenesis of the tryosines in the capsid proteins that would usually undergo 
phosphorylation would allow the virus to escape detection and degradation by the host cell, and 
therefore improve transduction.  
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Studies were conducted to test this hypothesis and mutations in various tyrosine residues 
of AAV2/2, specifically Y444F and Y730F, were found to have up to a 29-fold increase in gene 
expression in hepatocytes after IV administration of the vectors to C57BL/6 mice (59, 67). 
Currently, site-directed mutagenesis of other AAV serotypes has also shown increases in 
transduction efficiency. Petrs-Silva et al. also observed increases in transduction efficiencies of 
over 20-fold compared to wild-type capsids for AAV2/2, AAV2/8, and AAV2/9 (59, 67, 84). 
The tryosines that are mutated for each individual serotype requires optimization, but the best 
known mutations are AAV2/2(Y444F), AAV2/2(Y730F), AAV2/8(Y733F), and 
AAV2/9(Y446F) (67).  
Each of these capsid mutations reduced the dosage requirement for injection, broadened 
the tropism of the vector for the neural retina, and enhanced the diffusion of the vector across the 
retina in mouse models (67). Thus, AAV2/8(Y733F), containing a tyrosine mutation in the 
AAV8 capsid proteins, was found to finally deliver long-term rescue in one mouse model of 
photoreceptor degeneration; the rd10 mouse that contains a mutation in the β subunit of PDE6 
(67, 85). Currently, this AAV2/8(Y733F) serotype is a commonly used viral vector for research 
ongoing in pre-clinical models of retinal dystrophic diseases. 
In the retina, the tropism of the viral capsid is not the only condition that determines cell-
specific targeting efficiencies. Although it is necessary to choose the AAV capsid serotype that 
most efficiently targets the cell of interest, and to make mutations within the tyrosine residues of 
the capsid proteins that may increase transduction efficiency to this cell of interest, the 
localization of the AAV vector is also important for cell targeting. The site of the AAV delivery 
will affect the vector’s ability to reach certain retinal cells, and may enhance or block their 
ability to be transduced by the virus.  
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Within the retina there are two main routes of viral administration by injection: 
intravitreal and subretinal (67). Intravitreal injections deposit the AAV vector within the vitreous 
of the eye, which will allow for viral deliver to the retinal ganglion cells and Müller glial cells. It 
is an ideal route of delivery, as anti-angiogenic therapies for conditions such as diabetic 
retinopathy have allowed for intravitreal injections to become a standard practice by ophthalmic 
clinicians (67). Currently, researchers are looking into engineered AAV vectors that would be 
able to pass through the retinal cell layers after intravitreal delivery (86). However, currently 
there are no AAV serotypes that are able to efficiently transduce the RPE or photoreceptor cells 
following intravitreal injection. 
Subretinal injections allow for the targeting of the RPE or photoreceptor cells. This 
method delivers the virus into the space between the RPE and photoreceptors, creating a 
temporary retinal detachment termed the “subretinal bleb.” This retinal detachment will naturally 
heal itself following the uptake of the virus by the cells and diffusion of the diluent solution (67).  
Subretinal injections are clinically used for human patients, but unlike intravitreal 
injections these require an invasive surgical procedure. In humans, the surgical procedure 
involves a partial vitrectomy to allow for an increase in the volume of the AAV being delivered, 
and also to relieve intraocular pressure. For mice, however, it is not possible to carry out the 
vitrectomy procedure. It is still possible to perform the subretinal injection of the virus, but it 
takes careful skill and practice and will alter the pressure of the eye and cause for delays if 
second injections may need to be performed.  
Additionally, the mouse eye has an enlarged lens in comparison to humans, and the lens 
must be avoided during the surgical procedure (Figure 9). Damage to the lens tissue will lead to 
cataract formation and a loss of vision for the mouse. Therefore, for both mice and humans, the 
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subretinal injection surgical procedure is technically more challenging than an intravitreal 
injection and has a higher potential for surgical morbidities (67). However, it is the only current 
method for achieving transduction of the RPE and photoreceptor cells. Injections of the current 
known AAV serotypes into the subretinal space are able to transduce the RPE cells with 100% 
efficiency in the location of the subretinal bleb, and approximately 20-80% transduction 
efficiency of the photoreceptor cells in the location of the subretinal bleb, depending on the AAV 
serotype used to deliver the transgene (67). 
 
 
Figure 9. Schematic of the Mouse Eye. Anatomical structures of the mouse eye depicted in 
various colors. In comparison to the human eye, the mouse eye retains similar structures, but it 
lacks the macula and has an enlarged lens with a smaller amount of vitreal fluid. Most surgical 
procedures in the rodent eye must avoid the larger lens and are therefore performed most often 
along the base of the eye near the optic nerve (Adapted from 87). 
 
In addition to localized delivery, the viral titer is important for transduction of the retinal 
cells. In the current human trials, the maximum reported dosage of AAV has been 1.5 x 10
11
 
particles (67). This has been safe and well tolerated in the human patients, and currently no 
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cellular or humoral immune responses to the virus have been noted (67). For animal studies, 
higher viral titers have been utilized, with the highest dosage being 2.7 x 10
13
 particles in non-
human primates and 6.4 x 10
13
 particles in canines. No immune reaction to this higher viral 
delivery has been noted in these animal models (67). However, viral titers at higher levels than 
10
13
 have been noted to cause toxicity to the retinal cells, and/or inflammatory responses within 
the eye (67). This would suggest that lower viral titers would be safer for use in human clinical 
trials. However, deciding whether to use high versus low titers of the AAV virus depends on 
which cells are to be targeted. Lower doses of AAV have been shown to efficiently target the 
RPE cells, but higher titers have been necessary to efficiently transduce the photoreceptor cells. 
Lastly, once the correct gene therapy vector has been chosen, the method of delivery 
determined, and the viral titer decided, the clinician must then be concerned about safety. 
Immune responses to the viral injections have been a concern following initial gene therapy trials 
for human patients. Eleven children with Severe Combined Immunodeficiency Disease-XI 
received the cc cytokine receptor cDNA in a Moloney retrovirus. Sadly, the vector integrated and 
caused insertional mutagenesis and leukemia in 4 of the children (61, 88-89). The gene therapy 
treatment itself was successful, but the adverse side effects, especially in young children, halted 
clinical trials using gene therapy for a period of time due to concerns with mutagenesis and 
potential adverse immune reactions. 
For gene therapy utilizing AAV viruses, as these are non-pathogenic, safety concerns 
mainly arise from whether or not the host cell will produce neutralizing antibodies to block long-
term transgene expression. Neutralizing antibodies to AAV2 have been noted after the first 
injection of a gene therapy virus, but ocular re-administration of the viral vectors to the 
contralateral fellow eye have been studied in animal models and allowed for safe and efficient 
33 
 
 
gene transfer to both eyes (67, 90). Thus, the presence of neutralizing antibodies do not block the 
effect of the virus in the contralateral eye, possibly due to the retinal-blood barrier of the RPE 
and choroid that makes the eye more immune-privileged than other organs. If this is the case, 
neutralizing antibodies could pose a problem for second injections near the site of the original 
injection bleb in the same eye. 
 
GENE THERAPY CLINICAL TRIALS 
There are currently human clinical trials using AAV gene therapy. In the eye, there are 
currently 4 human clinical trials for LCA, a recessive blinding disorder caused by a mutation in 
RPE65 (NCT00999609; NCT00821340; NCT01496040; NCT00481546). As previously 
mentioned, RPE65 acts as an isomerase in the visual cycle that converts all-trans retinyl esters to 
11-cis retinal within the RPE in order for 11-cis retinal to be available for binding to opsin in the 
photoreceptor OS to make a molecule of rhodopsin (10, 58, 91). Recessive mutations in RPE65 
are phenotypically heterogeneous, and can lead to either LCA or other retinal degenerative 
diseases, such as RP. For LCA, RPE65 mutations account for approximately 5-10% of cases, and 
disease symptoms are present at birth or within the first months of life (58, 92-95). Diagnosis is 
confirmed after examining ERG and pupillary responses to light, both of which will be abnormal 
in LCA patients (59, 92, 96-98).  
The LCA clinical trial began after conclusive gene therapy results using a canine model 
with a mutation in RPE65. This model, the Briard dog, lacks the RPE65 protein which is then 
replaced using delivery of the RPE65 cDNA packaged into the AAV2/2 virus and injecting this 
viral vector into the subretinal space of the eye. Visual function was restored in this canine 
model and has been sustained for over 7.5 years at this time (10, 59, 76, 99-102). 
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The LCA human clinical trial began in 2007, with enrollment in 3 locations: the 
Children’s Hospital of Philadelphia /Second University of Naples, Italy (phase I/II; 
NCT00516477), Moorfields Eye Hospital/University College London, UK (phase I; 
NCT00643747), and the University of Pennsylvania/University of Florida/National Eye Institute 
(phase I; NCT00749957) (58, 103-106). The initial LCA2 Phase I clinical trial consisted of 3 
patients between 19-26 years of age (59). They received a low dose injection of the gene therapy 
virus in the eye with the worst disease progression to examine whether or not the viral gene 
therapy vector was safe in human patients. These patients displayed improved vision in dim light 
settings as little as two weeks after treatment. Pupillary responses to light were improved in each 
of the 3 eyes injected with the gene therapy virus, becoming at least 3 times more sensitive to 
light than its original baseline response. Navigation within an obstacle course was also improved 
in these patients. This efficacy of the gene therapy treatment persisted through the 1.5 year 
follow-up time-point (59, 107).  
The 1.5 year data presented two key benefits to AAV gene therapy research field. One, it 
confirmed that the transgene expression after AAV delivery is stable in human patients over time 
and not degraded by the host. Two, the AAV2-mediated gene transfer to the human retina did not 
cause a cytotoxic T-cell response in the patients (59). However, there were still some unexpected 
findings to the clinical trials. None of the patients had recordable ERGs, in contrast to the results 
of the canine models after gene therapy, suggesting a possibility of continuing degeneration in 
the patients after gene therapy treatment.  
However, more than 30 patients have now been treated using this clinical gene therapy 
vector. The clinical benefit has remained stable in the treated patients, with no adverse side 
effects. As would be expected by the amount of photoreceptors present within the retina, younger 
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patients responded better to the treatment than patients who were older in age (58, 107-109). 
These current human clinical trials using AAV gene therapy for LCA have rejuvenated the gene 
therapy community, and have brought about new research studies for using gene therapy to treat 
human patients with other retinal degenerative diseases. 
Besides the eye, AAV-mediated gene therapy treatments have been used for other human 
diseases. Hemophilia B, which is an X-linked bleeding disorder caused by the lack of clotting 
Factor IX (FIX), has three phase I clinical trials using AAV2 (59). This disease was chosen since 
it is caused by a single gene, and only a 1% improvement in the physiological levels of FIX is 
able to improve the severe bleeding phenotype in human patients. This rescue has already been 
noted after a single administration of AAV2/2-FIX into the muscle or liver of murine and canine 
models of hemophilia B (59, 110-115).  
The initial clinical trials for hemophilia B were run by Avigen, Inc., and demonstrated 
that the treatment was safe in human patients, and there was small improvement in two of the 
patients in the trial (59, 116). Dose escalation trials have shown no toxicity effects of the AAV 
gene therapy treatment. However, these patients were only able to improve after administration 
of the highest gene therapy viral dose, and the improvement only lasted for approximately 8 
weeks before the host immune response blocked the effects of the transgene (59, 117).  
Currently, a scAAV2/8 viral vector was utilized to deliver FIX to human patients with 
hemophilia B. The early data presented for this trial has shown that patients have maintained 
improvement for over five months after treatment, with no adverse immune response to this viral 
vector (59). Overall, the gene therapy trials are promising treatments for human diseases, 
especially in regards to the eye.  
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However, there are still many important factors necessary for achieving human clinical 
trials using AAV gene therapy. For efficacious gene therapy results, as previously mentioned, 
one must pay attention to the route of delivery, dosage, viral serotype, and immune response in 
order to reach long-term clinical improvement in the disease state. Along with each of these 
factors, one must also determine the correct promoter to drive gene expression. The current LCA 
trial is being conducted using a ubiquitous promoter, which could deposit the gene of interest in 
cells other than the RPE cells. Ongoing research studies are now using cell-specific promoters in 
order to ensure that the gene is only expressed in the cells where it would naturally be translated 
in a healthy individual, and no expression would occur in an off-target fashion.  
It is also important for scientists to determine which patients may benefit from gene 
therapy. For instance, patients with the P23H mutation in RHO have the most common mutation 
leading to RP in North America (43). Therefore, there are many individuals who would be able 
to benefit from gene therapy for this mutation. However, the disease phenotype caused by this 
mutation is mild, and patients retain vision until old age. In contrast, there are disease-causing 
mutations for RP that cause severe disease phenotypes, such as mutations within the PDE6α or β 
subunit (43). Patients with these mutations typically present with disease in childhood, and 
would have a greater lifetime that would benefit from gene therapy treatment.  
One limitation for gene therapy in patients who are effected by disease at a young age 
would be the ability to diagnose these patients early enough to provide the treatment when it 
would be effective. All of this knowledge of AAV serotypes and cell-type specific promoters has 
brought about the potential for treating retinal degenerative diseases that are currently 
untreatable. The results of the current clinical trials show promise, and the new goals are to find 
the most efficient methods to traffic the AAV vector to the appropriate target cells in the retina 
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and maintain adequate transgene levels to provide long-term survival. Now that there are gene 
therapy vectors available for treating patients with retinal diseases, it is important to verify these 
potential therapies in animal models before applying them in human studies.  
 
PART IV: PRE-CLINICAL EFFICACY 
ANIMAL MODELS OF HUMAN DISEASES 
Recently, animal models have become an important system for learning about 
mechanisms of human disease and they are used to test new therapeutic treatments before they 
are ready for human clinical trials. The same has been true in the field of ophthalmology. Back in 
1924, Keeler identified the first rod-less mouse model (118). This mouse model became the first 
identified spontaneous model of photoreceptor degeneration, and since then the mouse has 
become a key organism to study various diseases and therapies for photoreceptor degenerations.  
There are now a variety of mouse models with known genetic defects for studying RP. 
Luckily, many of the genes mutated in human patients show the same disease progression and 
phenotype in the mouse as in the human patients. In this way, mouse models of RP are beneficial 
for studying potential therapies to treat these human diseases (10, 119). Additionally, mice have 
only an average lifespan of approximately two years, so for many mouse models the onset and 
progression of retinal degeneration occurs rapidly and is easily visible on examinations such as 
ERG.  
For retinal degenerative diseases, mouse models have been utilized to study gene therapy 
treatments, and to determine if long-term visual rescue can occur after delivery of the gene 
therapy virus. However, most animal studies have focused on the delivery of transgenes to the 
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RPE, such as the studies leading to the LCA clinical trial (61, 120). Disorders such as RP, 
however, are typically associated with mutations within the photoreceptor cells, not the RPE.  
Currently, until the manuscript in chapter 4 of this dissertation, there was only one 
published study that provided long-term rescue using AAV to a mouse model with a mutation in 
the photoreceptor cells; a mutation in the PDE6β subunit (61, 85). This study was the first to 
provide long-term and functional rescue of a mouse model with a mutation in PDE6β, however 
scientists argue whether or not the rescue effect was due to the improved efficacy of the 
AAV2/8(Y733F) serotype used in this study or to the fact that the mice were dark-reared in order 
to substantially slow down the rate of retinal degeneration (67, 85). 
Further studies should utilize this AAV2/8(Y733F) serotype to transduce the 
photoreceptor cells; however they should test this gene therapy vector in an animal model of 
more rapid degeneration than the dark-reared mice of the previous study. The goals of animal 
studies will be to find a pre-clinical model to test therapeutic treatments for human patients. 
These pre-clinical animal models can then be used to identify the efficacy and safety of these 
treatment options over time, and whether or not they can only be used to slow the disease 
progression, or as a potential cure for the human disease.  
In 2009, Sakamoto et al. discovered two mouse lines during N-ethyl-N-nitrosourea 
(ENU) genetic screenings that have a missense mutation within the α subunit of PDE6: 
Pde6αnmf282/nmf282 and Pde6αnmf363/nmf363 (121). Both mice have significant photoreceptor 
degeneration after 2 weeks of age (Figure 10). However, these two mouse models were 
characterized through 1 month of age using histology and ERG analysis, but were not 
characterized longer than 1 month of age. I hypothesized that one of these pre-clinical mouse 
models, the Pde6αnmf363/nmf363 mouse, which has a rapid disease onset and progression, could be 
39 
 
 
both characterized to have disease progression and phenotypes similar to human RP patients, and 
could then be utilized to test for long-term gene therapy rescue of visual function that could lead 
to human clinical trials for RP caused by mutations in PDE6A. 
 
 
Figure 10. Histological analysis of a mouse model of retinitis pigmentosa. Histological 
analysis of retinas from C57BL/6J- Pde6a
nmf363/+
 and C57BL/6J- Pde6a
nmf363/nmf363
 at P12, P14, 
P19 and P36. All sections were stained with hematoxylin-eosin and photographed at the same 
magnification (200×). Scale bar represents 50 µm (Adapted from 121). 
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Chapter 2: Establishment of temporal and biochemical characteristics of photoreceptor 
neurodegeneration in native Pde6a
nmf363/nmf363
 mice**
,
*** 
**This chapter is adapted from a previously published manuscript: Wert, K.J., Davis, R.J., 
Sancho-Pelluz, J., Nishina, P.M. and Tsang, S.H. (2013) Gene therapy provides long-term visual 
function in a pre-clinical model of retinitis pigmentosa. Hum. Mol. Genet., 22, 558-567. 
 
***This chapter is also a modified version of data collected for the RD-CURE Consortium to 
begin human clinical trials using this gene therapy virus between Columbia University Medical 
Center, NY, and the University of Tübingen, Germany. 
 
ABSTRACT 
Retinitis pigmentosa (RP) is a photoreceptor neurodegenerative disease. Patients with RP 
present with the loss of their peripheral visual field, and the disease will progress until there is a 
full loss of vision. Approximately 36000 cases of simplex and familial RP worldwide are caused 
by a mutation in the rod-specific cyclic guanosine monophosphate phosphodiesterase (PDE6) 
complex. However, despite the need for treatment, mouse models with mutations in the alpha 
subunit of PDE6 have not been characterized beyond 1 month of age. We proposed to establish 
the temporal progression of retinal degeneration in the Pde6a
nmf363
 mouse eyes through 
longitudinal studies. We used histology, autofluorescence (AF) and infrared (IR) imaging to 
examine the appearance of the retinal cell layers and retinal pigment epithelium (RPE) that are 
affected in human RP patients. We also used electroretinograms (ERGs) to measure both 
photoreceptor-specific and global retinal visual function in the Pde6a
nmf363
 mice. We found that 
by 2 months of age, the number of photoreceptor cell nuclei is roughly halved in comparison to 
the 1 month time-point, and this degeneration continues until all photoreceptor cell nuclei have 
undergone degeneration by 4 months of age. Additionally, both loss of cone cell function and 
RPE atrophy are present by 5 months of age in these mice. The Pde6a
nmf363
 mice mimic human 
RP caused by mutations in PDE6A, and the establishment of the temporal and biochemical 
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characteristics of photoreceptor neurodegeneration in the Pde6a
nmf363
 mice allows for future 
studies to test therapeutic options using this animal model, since the progression of RP can be 
monitored using these various methods and compared to the established time-course of 
degeneration. 
 
INTRODUCTION 
Neurodegenerative diseases, such as retinitis pigmentosa (RP) and age-related macular 
degeneration (AMD), are due to photoreceptor cell death (42). In patients with these diseases, 
not only is there a loss of vision, but a loss of the quality of life since they must rely on others for 
daily activities such as reading, walking, or driving. RP is a common blinding retinal 
degenerative disease with no current treatment, and causes human RP patients to lose their night-
time vision and peripheral visual field over time. RP continues to progress until all visual 
response is extinguished.  
Approximately 36000 cases of simplex and familial RP worldwide are caused by a 
mutation in the rod-specific cyclic guanosine monophosphate phosphodiesterase (PDE6) 
complex (122). The PDE6 complex is composed of catalytic (PDE6α and PDE6β) and regulatory 
(PDE6γ) subunits (22, 123). However, despite the need for treatment, only mouse models with a 
mutation in the beta subunit of PDE6, such as Pde6βrd1, Pde6βrd10 and Pde6βH620Q, were utilized 
for pre-clinical studies (124-131). Mouse models were only recently discovered with mutations 
in the gene encoding the alpha subunit of PDE6 for use in studying this disease (121). These 
models, Pde6αnmf282 and Pde6αnmf363, contain similar mutations to those found in human patients 
with RP (OMIM 180071; 121). The temporal and biochemical characteristics of photoreceptor 
neurodegeneration in these mice have shown that there is a progressive loss of photoreceptors 
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and visual function over time from 2 weeks to 1 month of age. This appears to mimic the clinical 
phenotype of recessive RP found in human patients, however, long-term data beyond 1 month of 
age is missing for this pre-clinical model of RP.  
We utilized longitudinal studies to establish the temporal and biochemical characteristics 
of photoreceptor neurodegeneration over time in one of the mouse models with a mutation in the 
alpha subunit of PDE6: Pde6αnmf363. This mouse model displayed similar RP progression and 
phenotypes to human RP patients with mutations in PDE6A. Therefore, this is a valid pre-clinical 
model of human RP caused by mutations in the alpha subunit of PDE6 and can be utilized to test 
potential therapeutic options for RP. Treatments can be monitored for beneficial effects using the 
various non-invasive imaging methods in this study and comparing the treatment to the 
established time-course of degeneration for this pre-clinical model. 
 
RESULTS  
Early photoreceptor neurodegeneration in the Pde6αnmf363 mouse. 
Sakamoto et al. examined histology through post-natal (P) day 36, when only one row of 
photoreceptor cell nuclei was detected (121), but to utilize this mouse model for therapeutic 
treatments we hypothesized that there would be a time-point in which there would be a full loss 
of the photoreceptor cells, both rods and cones. First, we examined the photoreceptor inner and 
outer segments (IS and OS, respectively) at 1 month of age using electron microscopy to 
replicate the findings in Sakamoto et al. Compared to a C57BL/6J (B6) wild-type mouse, the 
Pde6αnmf363 mouse has a dramatic reduction in the IS and OS of the photoreceptor cells by 1 
month of age (Figure 1A-B). We then compared a histological section of the retina of a B6 wild-
type mouse at 5 months of age (Figure 1C) to a histological section of the retina of a Pde6αnmf363 
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mouse at 5 months of age (Figure 1D) and found that the photoreceptor cell nuclei, IS, and OS 
have completely degenerated by 5 months of age in the mutant mouse model. 
Therefore, to determine at what age prior to 5 months the photoreceptor cells fully 
undergo degeneration, we quantified the photoreceptor ONL thickness in a longitudinal study 
from 1 to 8 months of age. At 1 month of age, as previously determined by electron microscopy, 
there is a significant decline (approximately 50%) in the thickness of the ONL in the Pde6αnmf363 
mice compared with B6 wild-type mice (Figure 1E). The ONL cell thickness is approximately 
halved between 1-2 months of age, and all photoreceptor cells are lost by 4 months of age 
(Figure 1E). Thus, this pre-clinical model of RP has a rapid rate of degeneration, but follows the 
degeneration pattern of the photoreceptor cells found in patients with RP caused by mutations in 
PDE6A, where all cells are lost progressively during the lifespan.  
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Figure 1. Loss of photoreceptor cells in the Pde6αnmf363 mice. Electron microscopy image of a 
1 month-old C57BL/6J (B6) wild-type retina with healthy inner (IS) and outer segments (OS) 
(A). The IS and OS are severely degenerated and shortened in the Pde6αnmf363 mouse retina at 1 
month of age (B). Magnification: 4000X. H&E stained retinal section of a 5-month-old 
Pde6αnmf363 mouse retina (C), and a B6 control mouse (D). Scale bar: 600 µm. Quantification of 
the thickness of the ONL by counting the columns of photoreceptor nuclei in the Pde6αnmf363 
mouse retina from 1 to 5 months of age (E). Error bars show SEM for each time point. N ≥ 3 
mice. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; IS, inner 
segments; OS, outer segments; RPE, retinal pigment epithelium. 
 
Global loss of visual function in the Pde6αnmf363 mouse. 
 The degeneration of the photoreceptor cell layer, from some remaining cells at 1 month 
of age to the full loss of photoreceptors, rods and cones, by 4 months of age, suggests that the 
Pde6αnmf363 mice will continue to lose visual function after 1 month of age until there is no 
longer a visual signal present by 4 months of age. This is similar to human RP patients, who 
present with night-time loss of vision, then tunnel vision (the loss of the rod cells), until the 
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entire visual field is lost when the cone cells degenerate secondary to the rod cells. To confirm 
that this happens in the mouse model, we tested the Pde6αnmf363 mice using electroretinograms 
(ERGs) in a longitudinal study.  
First, we examined representative traces at different time-points of analysis. At 2 months 
of age, an ERG trace from the Pde6αnmf363 mouse has severely attenuated global visual function 
compared to a B6 wild-type mouse (Figure 2A).  This visual response in the mutant mouse is 
extinguished by 5 months of age, after the histological loss of all photoreceptor cell nuclei 
(Figure 2B). Quantification of ERG global visual function responses over time followed this 
pattern, with a severely attenuated visual function response at 1 month of age. The visual 
response declined through 3 months of age, and only a background response is visible from 4 to 
9 months of age, as would be expected with the loss of the photoreceptor cells by 4 months of 
age as seen in histology (Figure 2C). 
Since the loss of function of PDE6α leads to rod cell death, followed later by the 
secondary death of the cone cells, we examined ERGs specific to the photoreceptor cells. The 
ERG traces in Figure 2A displayed a loss of the ERG a-wave by 2 months of age in the 
Pde6αnmf363 mouse. The a-wave is a photoreceptor cell-specific visual function response, so this 
supports the photoreceptor neurodegeneration seen in histological sections of the Pde6αnmf363 
mutant retinas. We then quantified the maximum a-wave amplitudes from 1-9 months of age. As 
expected by the loss of the ONL, the photoreceptor cell-specific visual response was severely 
attenuated by 1 month of age in the Pde6αnmf363 mouse, and declined to almost no visual response 
by 2 months of age (Figure 2D). 
Individual examination of the rod and cone cells using a dim-light scotopic and a 
photopic ERG setting, respectively, displayed the expected RP phenotype in the mouse model 
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that is seen in human RP patients. ERG traces at 5 months of age, a time when both the rod and 
the cone photoreceptor cells should be lost, showed no ERG response in a Pde6αnmf363 mutant 
mouse when compared to a B6 mouse for both the rod and cone cell-specific ERG recordings 
(Figure 2E-F). We quantified the rod cell-specific ERG responses through 9 months of age, and 
found a loss of rod cell visual response in comparison to B6 control mice over time (Figure 2G). 
We also quantified the cone cell-specific ERG response beginning at 3 months of age, the latest 
time in histology when photoreceptor cells were still visible in the retina, through 9 months of 
age. Cone cell visual function was declined at 3 months of age in the Pde6αnmf363 mice, but still 
present, as would be expected if cone death was secondary to the rod degeneration (Figure 2H).  
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Figure 2. Loss of global visual function in the Pde6αnmf363 mice. Representative scotopic 
maximum ERG traces for a C57BL/6J (B6) control mouse (black) and a Pde6αnmf363 mouse (light 
gray) at 2 months of age (A), and 5 months of age (B). Maximum scotopic b-wave amplitudes in 
B6 mice and Pde6αnmf363 mice monthly between 1 and 9 months of age (C). Maximum scotopic 
photoreceptor-mediated a-wave amplitudes (shown as positive values) in B6 mice and 
Pde6αnmf363 mice monthly between 1 and 9 months of age (D). Representative scotopic dim light 
rod-specific ERG traces of a B6 control mouse (black) and a Pde6αnmf363 mouse (light gray) at 5 
months of age (E), and representative photopic single flash cone-mediated ERG traces for a B6 
control mouse (black) and a Pde6αnmf363 mouse (light gray) at 5 months of age (F). Dim light 
rod-specific scotopic b-wave amplitudes in B6 mice and Pde6αnmf363 mice monthly between one 
and 9 months of age (G). Photopic cone-specific b-wave amplitudes in B6 mice and Pde6αnmf363 
mice from 3 to 9 months of age (H). B6 mouse ERG results did not vary over the 9-month 
testing period so only the first result is shown in the charts for visualization purposes. Error bars 
show SEM for each time point and was calculated using t-test analysis. N≥ 3 mice.  
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Increased hyperfluorescence and retinal pigment epithelial atrophy over time in the 
Pde6αnmf363 mouse. 
 Human patients with RP present with increased autofluorescent particles, thought to be 
lipofuscin accumulation, in the retinal pigment epithelium (RPE) over time. In addition, they also 
show signs of RPE atrophy and pigment migration after the loss of the photoreceptor cells. 
Autofluorescence (AF) imaging of a normal B6 mouse shows a clear retinal image (Figure 3A). 
In the Pde6αnmf363 mutant mouse, however, there is the presence of autofluorescent particles as 
early as 2 months of age, before the full loss of the photoreceptor cells, and this remains through 
at least 9 months of age, approximately half of the mouse lifespan (Figure 3B-C). Additionally, 
since photoreceptor cells were lost in the Pde6αnmf363 mice by 4 months of age, infrared (IR) 
imaging was used to determine if there were changes in the RPE of the mouse model after this 
time. IR imaging of a B6 wild-type mouse shows a normal RPE at 8 months of age (Figure 3D). 
In the Pde6αnmf363 mutant mouse, the presence of RPE atrophy appears at 5 months of age, and 
substantially increases over time through 11 months of age (Figure 3E-H; * denotes sites of 
RPE atrophy).  
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Figure 3. Presence of hyperfluorescent spots and retinal pigment epithelial atrophy in the 
Pde6αnmf363 mouse. Representative autofluorescence (AF) imaging of a 5-month-old C57BL/6J 
(B6) mouse eye (A) and a 5-month-old Pde6αnmf363 mutant mouse eye displaying 
hyperfluorescent spots indicative of visual loss (B). These hyperfluorescent spots persist at 9 
months of age in the Pde6αnmf363 mutant mouse eye (C). Representative infrared (IR) images of a 
B6 control mouse at 8 months of age (D) compared to the Pde6αnmf363 mouse eye at 5 (E), 7 (F), 
9 (G), and 11 (H) months of age. Images for 5 and 7 months of age are taken from the same 
mouse, images from 9 and 11 months of age are taken from a second mouse for replication 
purposes. Increased IR reflectance represents RPE atrophy (*). IR imaging was obtained at 790 
nm absorption and 830 nm emission using a 55° lens. Images were taken of the central retina, 
with the optic nerve located at the center of the image. 
 
DISCUSSION  
Retinitis pigmentosa is a common blinding disorder that affects 1:3000 people (5, 38-41). 
Approximately 36000 of these cases are caused by a loss of function of the phosphodiesterase 6 
complex (122). Advances have been made using various research approaches, such as gene 
therapy, for mouse models with mutations in the beta subunit of PDE6 (124-131). However, 
mouse models were only recently discovered with mutations in the alpha subunit of PDE6; 
Pde6αnmf282 and Pde6αnmf363. Sakamoto et al. characterized these Pde6α mutant mouse strains 
through 1 month of age, but these mice were never examined beyond this time (121). This study 
replicates the results published by Sakamoto et al. on the retinal degenerative phenotype of the 
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Pde6a
nmf363
 mouse model at 1 month of age, and then extends the observation through 11 months 
of age; half of the mouse lifespan. Additionally, this study utilized non-invasive imaging 
technology to establish the time-course of degeneration in this pre-clinical model. These tests can 
be directly compared to those used in human RP patients, along with providing new methods for 
analyzing potential therapies in this model for the future. 
We analyzed the photoreceptor cell survival in a longitudinal study extending from 1 to 5 
months of age. We found that a complete loss of ONL photoreceptor cell nuclei occurred in the 
mutant eye by 4 months of age. ERGs displayed similar findings, where the visual response was 
severely attenuated after 2 months of age, and cone cell-specific ERG responses declined by 4 
months of age. We also found that rod-specific visual function was lost early in the Pde6αnmf363 
mutant mouse, as would be expected with a rod-cone dystrophic disease like RP. However, for 
the dim-light scotopic ERG, there was a high level of background from the machine causing 
increased amplitudes and variability in these responses. The ERG recordings for the maximum 
rod-cone scotopic a-wave amplitude may be a better option for deciphering the loss of the rod 
cell response after a threshold amount of rod cells have degenerated, rather than the dim-light 
scotopic ERG setting. However, even with variable rod cell ERG recordings, we found that cone 
cell function is lost over time secondary to that of the rod response. This supports the use of this 
mouse model to study human RP, both mechanistically and using potential therapeutic 
treatments.  
Furthermore, we examined the retinas using non-invasive live imaging techniques to 
determine if secondary changes occur in the mice that are found in human RP patients. We found 
an increase in fundus autofluorescence in the Pde6αnmf363 mutant mice, suggestive of an 
accumulation of lipofuscin particles that occurs in human patients with retinal degeneration. 
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Upon IR examination, RPE atrophy begins around 5 months of age, after the loss of the ONL 
and IS/OS in the mutant eyes, and this RPE atrophy increases dramatically by 7 months of age 
through 11 months of age, the latest time point that was studied. The use of non-invasive live 
imaging techniques in our examination of the mutant mice, as performed by clinicians on human 
RP patients, allows for a direct comparison of the degenerative features of the mice to the 
phenotypes of human RP. 
Our results establish the temporal and biochemical characteristics of photoreceptor 
neurodegeneration in the Pde6αnmf363 mouse model, as it was followed for approximately half of 
its lifespan. The results support that the Pde6αnmf363 mutant mice have similar biochemical 
characteristics of RP to that of human RP patients, and the disease progresses in a similar pattern 
over the mouse lifespan, as it would in a human RP patient. Therefore, we established that this is 
a useful mouse model to study potential therapeutic treatments for human RP. Additionally, we 
determined the time-points that would be most useful to this analysis, such as at 4 months of age, 
when all photoreceptor cells are lost and secondary effects, such as RPE atrophy, begin to 
develop in this mouse model. This study will allow for research to be conducted in a timely and 
cost-effective manner to test potential therapeutic options for clinical trials in human RP patients 
with a mutation in PDE6A.  
 
MATERIALS AND METHODS 
Mouse lines and husbandry 
C57BL/6J-Pde6αnmf363/nmf363, with a D670G mutation, herein referred to as Pde6αnmf363, 
mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Mice were maintained 
in the Columbia University Pathogen-free Eye Institute Annex Animal Care Services Facility 
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under a 12/12-h light/dark cycle. All experiments were approved by the local Institutional 
Animal Care and Use Committee (IACUC) under protocol #AAAB-4306. Mice were used in 
accordance with the Statement for the Use of Animals in Ophthalmic and Vision Research of the 
Association for Research in Vision and Ophthalmology, as well as the Policy for the Use of 
Animals in Neuroscience Research of the Society for Neuroscience. Pde6αnmf363 mice used in 
this study were bred from a colony of mice that has been previously reported (121). Pde6αnmf363 
are coisogenic in the C57BL/6J (B6) background; therefore, age-matched B6 mice were used as 
experimental controls (The Jackson Laboratory).  
 
Electron microscopy 
Electron microscopy was performed according to established protocols (132). Selected 
areas were trimmed for ultrathin sectioning and stained with uranyl acetate before electron 
microscopy observation. 
 
Histochemical analyses 
Mice were sacrificed and the eyes enucleated as previously described (133). Excalibur 
Pathology, Inc. prepared Hematoxylin & Eosin retinal sections. Quantification of photoreceptor 
nuclei was conducted on several sections that contained the optic nerve, as follows: the distance 
between the optic nerve and the ciliary body was divided into four, approximately equal, 
quadrants. Three columns of nuclei (how many cell nuclei thick) were counted within each 
single quadrant. These counts were then used to determine the average thickness of the ONL for 
each individual animal at each time. Averages and standard deviations were calculated from 
animals for each time point using t-test statistical analyses. Sectioning proceeded along the long 
53 
 
 
axis of the segment, so that each section contained upper and lower retina as well as the posterior 
pole. 
 
Electroretinograms 
Mice were dark-adapted overnight, manipulations were conducted under dim red light 
illumination, and recordings were made using Espion ERG Diagnosys equipment (Diagnosys 
LLL, Littleton, MA, USA). Adult B6 control mice were tested at the beginning of each session to 
ensure equal readouts from the electrodes for both eyes before testing the experimental mice. 
Pupils were dilated using topical 2.5% phenylephrine hydrochloride and 1% tropicamide (Akorn 
Inc., Lakeforest, IL, USA). Mice were anesthetized by intraperitoneal injection of 0.1 ml/10 g 
body weight of anesthesia [1 ml ketamine 100 mg/ml (Ketaset III, Fort Dodge, IA, USA) and 0.1 
ml xylazine 20 mg/ml (Lloyd Laboratories, Shenandoah, IA, USA) in 8.9 ml PBS]. Body 
temperature was maintained at 37°C using a heating pad during the procedure. Hand-made 
electrodes were placed upon the corneas and gonioscopic prism solution (Alcon Labs, Inc., Fort 
Worth, TX, USA) was applied to each eye. Both eyes were recorded simultaneously. A total of 
40–60 responses were averaged for each trial. All further detail on the ERG method has been 
described previously (134-135). We measured scotopic maximal b-wave ERG responses to 
assess inner retina function, scotopic maximal a-wave ERG responses to assess photoreceptor-
specific function, scotopic dim light maximal b-wave ERG responses to assess rod-specific 
function, and photopic maximal b-wave ERG responses to assess cone-specific function. 
Maximal responses were taken from the Espion readout in microvolts and quantified using t-test 
statistical analyses.  
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Autofluorescence imaging 
Fundus autofluorescence (AF) imaging was performed with a confocal scanning laser 
ophthalmoscope (OCT-SLO Spectralis 2; Heidelberg Engineering, Heidelberg, Germany) as 
previously described by others (136). Pupils were dilated with topical 0.5% tropicamide and 
2.5% phenylephrine before anesthesia was provided. A 55° field of view was captured with a 
resolution of 1,536 × 1,536 pixels. 
 
Infrared imaging 
IR fundus imaging was obtained with the Spectralis scanning laser confocal 
ophthalmoscope (Heidelberg Engineering, Carlsbad, CA, USA). IR imaging was obtained at 790 
nm absorption and 830 nm emission using a 55° lens. Images were taken of the central retina, 
with the optic nerve located in the center of the image.  
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Chapter 3: Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal 
Mouse Eye**** 
****This chapter is a modified version of a previously published manuscript: Wert, K.J., Skeie, 
J.M., Davis, R.J., Tsang, S.H., Mahajan, V.B. (2012) Subretinal injection of gene therapy vectors 
and stem cells into the perinatal mouse eye. J. Vis. Exp., e4286 10.3791/4286, 
DOI:10.3791/4286. 
 
ABSTRACT 
This surgical technique illustrates the injection of gene therapy vectors and stem cells into the 
subretinal space of the perinatal mouse eye. 
 
INTRODUCTION 
The loss of sight affects approximately 3.4 million people in the United States and is 
expected to increase in the upcoming years (137). Recently, gene therapy and stem cell 
transplantations have become key therapeutic tools for treating blindness resulting from retinal 
degenerative diseases. Several forms of autologous transplantation for age-related macular 
degeneration (AMD), such as iris pigment epithelial cell transplantation, have generated 
encouraging results, and human clinical trials have begun for other forms of gene and stem cell 
therapies (138). These include RPE65 gene replacement therapy in patients with Leber's 
congenital amaurosis and an RPE cell transplantation using human embryonic stem (ES) cells in 
Stargardt's disease (139-140). Now that there are gene therapy vectors and stem cells available 
for treating patients with retinal diseases, it is important to verify these potential therapies in 
animal models before applying them in human studies. The mouse has become an important 
scientific model for testing the therapeutic efficacy of gene therapy vectors and stem cell 
transplantation in the eye (55, 124, 141-142). In this video article, we present a technique to 
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inject gene therapy vectors or stem cells into the subretinal space of the mouse eye while 
minimizing damage to the surrounding tissue. 
 
PROTOCOL 
I.  ASSEMBLE DEVICES FOR THE SUBRETINAL INJECTION 
1. Purchase or make a 100 μm diameter needle from a glass capillary tube. This can be done 
manually by using a Sutter P-97 pipet puller or other similar equipment. The end of the capillary 
tube will be heated and pulled until it reaches the desired diameter (100 μm). A smaller diameter 
needle can be used for gene therapy vectors; however, this is the recommended diameter for cell 
injection without damage to the cells or the eye. Compared to steel needles, the glass capillary 
needle has a very fine, but blunt tip, to allow for visualization of the injection fluid and access to 
the subretinal space without causing retinal breakage. Clean these pulled needles if needed using 
70% ethanol, and store in a sterile container. A 15 cm sterile tissue culture dish with tape to hold 
the needles in place is one way in which to keep the injection needles covered and in a sterile 
environment. At this point, complete the set-up within the surgical room where the procedure 
will take place. It is easiest to keep all equipment in the surgical room at all times in order for it 
to remain sterile, especially if this procedure is done within a barrier facility. 
 
2. Aspirate silicone into the injection needle and eject the silicone to leave a coating along the 
inner walls of the needle. The silicone coating maximizes the passage of cells and viruses 
through the needle bore, which would otherwise stick to the inner glass capillary walls. 
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3. Obtain an approximately 8 cm length of sterile plastic tubing by cutting a 25 ¾-gauge blood 
collection set with luer-lock at the point directly after the needle (removing the needle from the 
tubing). 
 
4. Fill a 1 ml Sub-Q 26 5/8-gauge slip-tip syringe with sterile saline and remove the needle from 
the syringe. 
 
5. Attach the injection needle to the cut end of the plastic tubing and attach the syringe to the 
luer-lock at the other end. 
 
6. Aspirate sterile saline to fill the dead space in the tubing and capillary needle, ejecting some 
saline through the needle to ensure that it is correctly attached without any leakage. Next, 
aspirate a small, approximately 1 μl amount of air, into the tip of the injection needle. This will 
separate the saline from the injection fluid and provide a visual cue indicating the end of the 
injection fluid during the surgical procedure. The injection apparatus should be kept on a clean 
surface wiped down with 70% ethanol during the surgical procedure. Additionally, all equipment 
used during the surgical procedure should be cleaned both before and after with 70% ethanol, for 
the exception of the injection needles which should already be kept sterile and ready for use. 
These needles should be disposed of after surgery, and not re-used. 
 
7. Finally, aspirate injection solution containing the desired packaged gene therapy viral vector 
or stem cells. This can be done by taking up the injection solution into a sterile pipet tip, then 
pipetting the solution onto the surface of a sterile cell culture dish. The solution can now be 
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easily aspirated into the injection needle using the syringe. The amount needed will vary 
depending on the age of the mouse. For our purposes we use post-natal day 5 mice, which can be 
injected with 0.5-0.8 μl of injection fluid. Smaller amounts, 0.5 μl or less, can be used for 
younger mice and larger amounts, such as 1 μl, can be used for adult mice. The viral titer or 
number of cells needs to be determined based on the virus/cells being injected and their desired 
target tissue, as too many viral particles or cells in a small volume can lead to toxicity for the 
retinal cells. In the video, for visualization purposes, we have used 1.5 μl, a greater amount of 
dye than necessary to inject into the eye. 
 
II. ACCESSING THE SUBRETINAL SPACE 
1. Within the sterile surgical room, stabilize or anesthetize the mouse according to the locally 
approved animal handling protocol, which will vary by age of the mouse. Common anesthesia 
for adult mice includes the use of isoflurane gas or an intra-peritoneal injection of 0.1 ml/10g 
body weight of ketamine (100 mg/ml) and xylazine (20 mg/ml) in sterile saline. For perinatal 
mice, common anesthesia techniques include the use of isoflurane gas or cryoanesthesia 
(hypothermia). All anesthesia techniques must be approved by your local IACUC committee 
before use. We typically use post-natal day (P) 5 mice, although similar techniques can be 
applied to mice as young as P0 or to adult mice. The surgical procedure cannot begin until the 
mouse has ceased moving the limbs and no longer responds to toe pinches. For perinatal mice, 
they will become noticeably lighter in color since the blood flow will slow down, another key to 
knowing that they are fully under anesthesia. 
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2. In perinatal mice, use Vannas straight scissors to make an approximate 1.5 mm incision along 
the closed lid fissure. Be careful to cut at the indentation, where the eye will naturally open in the 
future. This ensures that the lids will heal and open properly during the development of the 
mouse. A surgical blade can be used for this purpose, although we prefer Vannas scissors since 
they reduce the risk of puncturing the eye during this procedure. In the video, the scissors were 
used to directly puncture and cut along the eyelid margin. When learning this technique, forceps 
should be used to lift the eyelid before cutting and reduce the risk of damaging the eye. 
 
3. Pull apart the eyelids with curved dressing forceps to proptose the eye and pinch the eyelids 
slightly underneath the eye to hold it proptosed for injection. If the lid incision made in step two 
is too large, the eye will slip back under the lids and prevent adequate exposure during the 
injection procedure. For adult mice, applying slight pressure around the eye with dressing 
forceps can hold the eye proptosed for injection. 
 
4. Make a small scleral incision at or posterior to the globe's equator by scratching the surface 
with a 15-degree microsurgery blade. This incision should be only large enough to pass the tip of 
the injection needle, but no larger than that. If preferred, a small, sharp needle such as an 
acupuncture needle can be used to make this incision into the subretinal space instead of the 
microsurgery blade. In darkly pigmented animals, a dark brown-pigmented tissue (the choroid-
retinal pigment epithelium) will become visible at the point of incision. In lighter pigmented or 
albino mice, a surgical marking pen can be applied to the tip of the microsurgery blade to leave 
an ink spot indicating the incision site. If clear (vitreous) fluid refluxes from the incision site, the 
blade was placed too deep and entered the vitreous cavity and the therapeutic virus or cells may 
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enter the intravitreal space during injection. For visualization purposes, we have made the 
incision to this point in the video. It is still possible to complete a subretinal injection in this case, 
however the retinal detachment caused by the presence of the injection fluid may not fully heal 
in this mouse. Therefore, care must be taken to cut only the outer surface of the eye and not 
through the retina before injection. 
 
5. Carefully insert the injection needle into the incision site and advance it parallel to the outer 
eye wall to enter the subretinal space. Advancing too close to the outer wall or too deep within 
the eye will direct the injection into the wrong location. The best method to understand whether 
the needle is in the correct location is to practice the technique. Practicing on lightly pigmented 
or albino mice can help to make precise and accurate injections into the subretinal space. This is 
because the needle and injection fluid is visible within these eyes. 
 
6. Apply light pressure to the syringe plunger and begin injection of the desired fluid. If the 
needle is correctly placed within the subretinal space, moderate backpressure will be felt. If the 
needle is within the vitreous, there will be significantly less backpressure and potentially some 
fluid reflux during the injection. If there is significant backpressure, hold the needle in place for 
at least an additional 15 seconds before removing the needle slowly. This will allow the high 
intraocular pressure to equalize instead of refluxing the injected virus or cells back out the 
incision site. Some of the air and saline may be injected into the subretinal space due to the 
increased pressure required during the injection procedure. Care should be taken not to over-
inject air or saline, since it can flush out the injected virus or cells from the eye. It is also possible 
to cause permanent retinal detachment from the presence of too much fluid injected into the 
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subretinal space. For visualization purposes, excess dye and air was injected into the subretinal 
space in the video. It can be clearly seen how some of the dye will be flushed back out 
of the subretinal space if too much is injected, but also how the air bubble remains within the 
subretinal space and does not disappear into the vitreous. This was used to emphasize that these 
injections were all within the correct location of the eye, so one can visualize how the needle 
should enter the incision site. All injections into the subretinal space cause a temporary retinal 
detachment due to the presence of the injection fluid. If the injection procedure is completed 
correctly, this temporary retinal detachment will heal within 24 hr and mice can be used for all 
further experiments. The eye may remain soft for approximately one week due to the surgical 
procedure, so a second injection should be avoided during this period of time. 
 
7. For neonatal mice, use the curved dressing forceps to gently push the eye back behind the lids 
and into the orbit. It may be useful to wait for a minute in order to allow the virus to settle within 
the subretinal space and not cause it to be flushed out of the incision site when gently pushing the 
eye back into its orbit. After surgery, one drop of 0.5% bupivacaine (marcaine) diluted to 0.25% 
in sterile saline from a 25-gauge needle can be placed at the injection site. Mice do not show 
overt signs of distress after subretinal surgery and the use of bupivacaine as a long-acting topical 
analgesic has been ample for the previous three years. Mice should always be monitored after the 
surgical procedure to look for any signs of distress; such as infection, swelling, or a decrease in 
the usual daily activities of the mouse. If these occur, the veterinarian should be notified and 
further pain medications such as buprenorphine (0.05 mg/kg) can be given as an intraperitoneal 
injection. 
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8. Wake the mouse from anesthesia according to locally approved animal handling protocol. The 
mouse should be kept on a heating pad to maintain normal body temperature as it wakes from the 
anesthetic. The surgical procedure should take less than five minutes to complete, not counting 
the time for the mouse to undergo anesthesia. Therefore, a heating pad is not necessary during 
the actual procedure, but may be needed while one is learning the technique as the procedure 
could take a longer duration of time. The mouse should not be placed back into a clean cage until 
it has begun to move around on its own. For neonates, gentle toe pinches will help for them to 
fully recover from the anesthesia, and they should regain their pink color and movement before 
being placed back with the mother. Mice should be monitored over time for any signs of distress 
as listed previously. 
 
RESULTS 
A drawing of the mouse eye is shown with major structures labeled for reference, with 
arrows displaying the locations for both intravitreal and subretinal injection surgical procedures 
(arrowheads, Figure 1). Gene therapy vectors, such as the lacZ lentiviral vector (Figure 2), can 
be injected using these locations. Additionally, stem cells, such as mouse embryonic stem cells 
(Figure 3), can also be transplanted at these sites in the mouse eye. 
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Figure 1. Schematic of the Mouse Eye with Injection Sites. A cartoon drawing depicting the 
structures of the mouse eye with sites for both intravitreal and subretinal injection procedures 
marked (arrowheads). 
 
1 μl of a lentiviral vector carrying the lacZ reporter gene driven by the cytomegalovirus 
(CMV) promoter (1x108 TU/ml, Lentigen Corporation, Figure 2A) was injected into the 
subretinal space of C57BL/6J mice. Eyes were enucleated at six weeks of age by blunt dissection 
and immersed in 1 mg/ml X-gal solution (5mM K3Fe(CN)6, 2 mM MgCl2, 0.02% NP40, and 
0.1% sodium deoxycholate) overnight at 37 °C. Eyes were fixed in 2% formaldehyde/0.2% 
glutaraldehyde for 30 min and sectioned on a microtome. LacZ reporter gene expression was 
detected as X-gal product (blue) in approximately 10% of photoreceptor cells (Figure 2B). The 
intracellular presence of lacZ expression and the intact surrounding tissues indicate the 
successful subretinal injection in the mouse eye. 
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Figure 2. Subretinal Injection of a Gene Therapy Viral Vector. A. Lentivirus vector map 
showing the lacZ reporter gene driven by the cytomegalovirus (CMV) promoter. B. Expression 
of the lacZ reporter gene in the retina in a six week old C57BL/6J mouse after subretinal 
injection at post-natal day five. RGC, retinal ganglion cells; INL, inner nuclear layer; IS, 
photoreceptor inner segments (arrow); ONL, outer nuclear layer (photoreceptors)(arrowhead); 
OS, photoreceptor outer segments. 
 
C57BL/6J mouse embryonic stem (ES) cells were labeled with a green fluorescent 
protein (eGFP, Wellcome Trust Sanger Institute). These cells were then collected and suspended 
in sterile phosphate-buffered saline and transplanted into the subretinal space of post-natal day 
(P)5 C57BL/6J mice, with approximately 1x105 cells injected per 1 μl. Eyes were enucleated at 
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two weeks of age by blunt dissection, fixed in a sucrose gradient and frozen in O.C.T. 
embedding medium (Tissue-Tek). Eyes were sectioned and visualized under fluorescence 
microscopy (Zeiss). The presence of GFP-labeled ES cells can be found within the subretinal 
space of the injected mouse eye (Figure 3A). Additionally, C57BL/6J-Tyrc-2j/J (C2J) mouse 
embryonic stem (ES) cells were electroporated with yellow fluorescent protein (YFP) and 
differentiated into retinal pigment epithelial (RPE) cells in vitro. After one month of 
differentiation, the YFP-labeled RPE-like C2J ES cells were suspended in sterile phosphate-
buffered saline and injected into the subretinal space of P5 C57BL/6J mice. At 15 weeks of age, 
a mouse was visualized using live-imaging autofluorescence for the presence of YFP within the 
retina (Spectralis Scanning Laser Confocal Ophthalmoscope, Heidelberg Engineering, Figure 
3B). 
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Figure 3. Subretinal Injection of Mouse Embryonic Stem (ES) Cells. A. A two week old 
C57BL/6J mouse after subretinal injection of green fluorescent protein (GFP)-labeled ES cells at 
post-natal day five. GFP-positive cells are visible within the subretinal space of the injected eye 
using fluorescence microscopy (Zeiss). Green, GFP-labeled ES cells (arrows); RGL, retinal 
ganglion layer; INL, inner nuclear layer; ONL, outer nuclear layer (photoreceptors); IS/OS, inner 
and outer photoreceptor segments; RPE, retinal pigment epithelium. B. A 15 week old C57BL/6J 
mouse retina shown using autofluorescence live-imaging (Spectralis Scanning Laser Confocal 
Ophthalmoscope, Heidelberg Engineering) for the presence of yellow fluorescent protein (YFP)-
labeled RPE-like C2J mouse ES cells within the retina. Subretinal injection of the RPE-like 
YFP-ES cells was performed at post-natal day five. 
 
DISCUSSION 
This video technique provides instructions on completing the subretinal injection surgical 
procedure successfully, and ensuring that the gene therapy vector or stem cells are placed in the 
location necessary to efficiently treat the ophthalmic disease. This technique allows for the 
targeting of retinal cells such as the RPE or photoreceptors, since it places the gene therapy 
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vectors or stem cell-derived tissues in the vicinity of these cells. Previous methods involved 
intravitreal injections, where the fluid is placed within the vitreous cavity and must migrate 
through the retina in order to target these specific areas. Intravitreal injection reduces the 
transduction of gene therapy vectors that target photoreceptors or the RPE, since not all viral 
particles will migrate into the correct location. Furthermore, stem cells are becoming 
increasingly popular to replace diseased RPE or photoreceptors, and these differentiated cells 
must be transplanted within the subretinal space (55). 
The critical step in this procedure is entry into the subretinal space, since this ensures the 
correct location of gene therapy vectors or stem cell-derived tissues in order to have therapeutic 
efficacy, along with reducing the potential for retinal detachment or damage to the surrounding 
eye tissue. Care must be taken to troubleshoot ahead of time; to be able to locate and inject the 
fluid into the subretinal space. This can be done through practice using colored dye and albino 
mice, as shown in the video, since the injection needle will not be visible within the eye of 
pigmented mice. After practice, the researcher will learn to feel the difference in pressure when 
the fluid is correctly placed within the subretinal space and be comfortable with the surgical 
procedure to complete it in a timely manner. 
There are some potential modifications for this surgical procedure. These injections can 
be performed on mice of different ages, although the amount of gene therapy vectors or stem 
cell-derived tissues injected could vary depending on the age of the mouse. Care should be taken 
to determine how much fluid will promote treatment for the ophthalmic disease, but not prolong 
detachment and damage to the retina. The pulled capillary needle can be modified to have 
different diameters. Smaller needles are sufficient for viral injections, but larger diameters may 
be better for cellular transplantation. In addition, the surgery can be performed on adult mice. 
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The eye tissue density will be much greater, so fresh, sharp surgical blades are required to 
penetrate into the subretinal space. In all cases, modifications can be made based on this protocol 
to complete a successful subretinal injection of a gene therapy vector or stem cell-derived tissue.  
All subretinal injections will cause a temporary retinal detachment due to the presence of 
the injected fluid within the subretinal space, but this detachment should heal within 24 hours of 
the surgical procedure. Mice can be carefully checked under a microscope for any remaining 
detachment. It is possible that some mice may not heal naturally even after a well-placed 
injection. All mice are able to undergo examination and experiments following this 24-hour 
time-period, however the eye may be soft due to a change in pressure from the injection 
procedure for up to one week. Therefore, one limitation of this technique is the ability to perform 
secondary injections during the first postoperative week. Another injection may not be possible 
during the immediate postoperative period, since the incidence of retinal detachment that does 
not heal after surgery is increased. It is advised to wait for a longer duration of time, as long as 
one month, before re-injecting the mouse eye. 
The mouse has become an important model organism to study ophthalmic disease and 
potential therapies that will lead to human clinical trials (143-146). A second limitation of this 
procedure is that not all cells are transfected with DNA vectors following subretinal injection, as 
they would be in a transgenic mouse model. However, this procedure may more closely 
approximate a clinical procedure in humans where not every cell is transfected. Thus, this 
technique can help to establish the feasibility for gene therapy viral vectors or stem cell-derived 
tissue transplantation therapy to treat age-related macular degeneration and other vitreoretinal 
diseases in humans. Future applications can include the use of different retinal cell promoters 
and differentiated stem cells, or even multiple injections using a combination of treatments. 
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MATERIALS AND METHODS 
The video component of this article can be found at http://www.jove.com/video/4286/ 
 
Table 1. Materials for the subretinal injection surgical procedure. 
 
Name 
 
Company Catalog Comments 
 
0.8-1.10 x 100 mm Capillary Tube (glass) 
 
 
Kimble Glass, Inc. 
 
34502 99 
 
 
Flaming/Brown Micropipette Puller 
 
Sutter Instrument 
 
P-97 
Narishige microforge can 
be used instead.  Catalog 
#MF-900 
 
 
Sigmacote 
 
 
Sigma Aldrich 
 
SL2-25ML 
 
Silicone 
 
Dubecco’s Phosphate Buffered Saline with Calcium 
Chloride and Magnesium Chloride 
 
 
Gibco-Invitrogen 
 
14040-133 
 
 
Safety-Lok 25 3/4G x 12” Blood Collection Set 
 
 
B-D Vacutainer 
 
367298 
 
 
1mL Sub-Q 26 5/8G Slip-Tip Syringe 
 
 
Becton-Dickinson 
 
309597 
 
 
0.5-10L Finnpipette II Adjustable-Volume Pipetter 
 
 
Fisherbrand 
 
21-377-815 
 
 
1-200L Natural Beveled Tips 
 
 
USA Scientific, Inc. 
 
1111-1700 
 
 
Discovery.V8 Stereo Microscope 
 
 
Zeiss 
 
MC1500 
 
 
60mm x 15mm Style Treated Polystyrene Cell 
Culture Dish 
 
 
Corning Incorporated 
 
430166 
 
 
Vannas Straight Scissors 
 
 
Storz Ophthalmics 
 
E3383 S 
 
 
Curved Dressing Forceps with Serrations Delicate 
 
 
Storz Ophthalmics 
 
E1408 
 
 
15 Degree Microsurgery Knife 
 
 
Wilson Ophthalmic Corp. 
 
 
091204 
 
 
Ketamine 
 
 
Ketaset III 
 
NADA #45-290 
 
 
 
Xylazine 
 
 
Lloyd Laboratories 
 
NADA #139-236 
 
 
 
Bupivacaine (Marcaine) 
 
 
AstraZeneca 
 
N/A 
 
70 
 
 
 
Buprenorphine  
 
 
Sigma Aldrich 
 
B9275 
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Chapter 4: Gene therapy provides long-term visual function in a pre-clinical model of 
retinitis pigmentosa** 
**This chapter is a modified version of a previously published manuscript: Wert, K.J., Davis, 
R.J., Sancho-Pelluz, J., Nishina, P.M., Tsang, S.H. (2013) Gene therapy provides long-term 
visual function in a pre-clinical model of retinitis pigmentosa. Hum. Mol. Genet., 22, 558-567. 
 
ABSTRACT 
Approximately 36 000 cases of simplex and familial retinitis pigmentosa (RP) worldwide 
are caused by a loss in phosphodiesterase (PDE6) function. In the preclinical Pde6αnmf363 mouse 
model of this disease, defects in the α-subunit of PDE6 result in a progressive loss of 
photoreceptors and neuronal function. We hypothesized that increasing PDE6α levels using an 
AAV2/8 gene therapy vector could improve photoreceptor survival and retinal function. We 
utilized a vector with the cell-type-specific rhodopsin (RHO) promoter: AAV2/8(Y733F)-Rho-
Pde6α, to transduce Pde6αnmf363 retinas and monitored its effects over an 11-month period (half 
of the mouse lifespan). We found that a single injection enhanced survival of photoreceptors and 
improved retinal function. At 6 months of age, the treated eyes retained photoreceptor cell 
bodies, while there were no detectable photoreceptors remaining in the untreated eyes. More 
importantly, the treated eyes demonstrated functional visual responses even after the untreated 
eyes had lost all vision. Despite focal rescue of the retinal structure adjacent to the injection site, 
global functional rescue of the entire retina was observed. These results suggest that RP due to 
PDE6α deficiency in humans, in addition to PDE6β deficiency, is also likely to be treatable by 
gene therapy. 
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INTRODUCTION 
Loss of vision, leading to a loss of independence in activities of daily living resulting 
from some neurodegenerative diseases, such as retinitis pigmentosa (RP) or age-related macular 
degeneration (AMD), is due to photoreceptor cell death (42). In patients with RP, initially, death 
of the rod photoreceptors will cause night blindness. This is followed by a deterioration of the 
peripheral visual field and may progress until all visual response is extinguished. Approximately 
36 000 cases of simplex and familial RP worldwide are caused by a mutation in the rod-specific 
cyclic guanosine monophosphate phosphodiesterase (PDE6) complex (122). In spite of the 
occurrence of this disease, no effective treatments are currently available to ameliorate this loss 
of vision.  
The PDE6 complex is composed of catalytic (PDE6α and PDE6β) and regulatory 
(PDE6γ) subunits (22, 123). There are several mouse models with mutations in the gene 
encoding the β-subunit, such as Pde6βrd1, Pde6βrd10 and Pde6βH620Q. These Pde6β mouse models 
have been useful for testing various drug and gene therapies, but in spite of this, most viral-
mediated gene therapy approaches have met with limited success (125-131). Recently, an adeno-
associated viral (AAV)2/8 gene therapy vector with a Y733F capsid mutation was shown to 
promote long-term rescue compared with the earlier AAV2 and AAV5 vector serotypes (85). 
Pang et al. improved visual function in the Pde6βrd10 mouse for 6 months using an AAV2/8 gene 
therapy vector.  
Mouse models have been described with mutations in the gene encoding the α-subunit of 
PDE6; Pde6αnmf282 and Pde6αnmf363, which have similar mutations found in human RP patients 
(OMIM 180071, 121). These mice mimic the clinical phenotype of recessive RP found in 
humans, where there is a progressive loss of photoreceptors and visual function, at a faster rate of 
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degeneration than that which occurs in the Pde6βrd10 mouse model (147). No therapeutic 
strategies have been tested on these Pde6α models, to either correct or slow the progression of 
the disease phenotype.  
In this study, we hypothesized that an AAV2/8 gene therapy vector can increase both 
photoreceptor survival and neuronal function in a mouse model with a mutation in the PDE6 α-
subunit. We utilized an AAV vector designed to specifically express wild-type PDE6α in the 
Pde6α mutant rod photoreceptor cells through the rhodopsin gene promoter: AAV2/8(Y733F)-
Rho-Pde6α. We delivered the AAV2/8(Y733F)-Rho-Pde6α virus into the right eye of 
Pde6αnmf363 mutant mice using a single subretinal injection. We then compared photoreceptor 
survival and visual function between the treated right eyes and the untreated left eyes of these 
mice. 
 
RESULTS  
AAV2/8(Y733F)-Rho-Pde6α vector map  
The AAV2/8(Y733F)-Rho-Pde6α gene therapy vector was created using a pZac2.1 
plasmid. The Pde6α complementary DNA (cDNA) fragment was inserted into this plasmid, 
along with 1.1 kb of the murine rhodopsin promoter, a Simian virus 40 (SV40) site, and poly(A) 
tail flanked by inverted terminal repeats (ITRs). This pZac2.1 plasmid with these sites inserted 
was used for packaging into the viral construct before subretinal injections (Figure 1).  
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Figure 1. Schematic representation of the AAV2/8(Y733F)-Rho-Pde6α vector. pZac2.1 
vector plasmid displaying the Pde6α complementary DNA (cDNA) fragment driven by 1.1 kb of 
the murine rhodopsin promoter. The Simian virus 40 (SV40) polyadenylation signal is located at 
the 3′ end of the cDNA. Arrows indicate the direction of transcription. 5′- and 3′-ITRs, inverted 
terminal repeat of AAV; AmpR, ampicillin-resistant gene; F1 ori, origin of replication. Scale bar: 
1 kb. 
 
Retinal transduction of AAV2/8 
To determine the transduction efficiency of AAV2/8 within the retina, a subretinal 
injection of AAV2/8-TurboRFP was administered to a litter of homozygous Pde6αnmf363 mutant 
mice. This vector expresses red fluorescent protein (RFP), which allows for the visualization of 
the cells transduced by the virus. After a single subretinal injection at post-natal day (P) five, 
RFP expression remained visible within the retina at P55, indicating that the virus was taken up 
by the retinal cells and survived for at least 2 months (Figure 2A). RFP expression was detected 
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within the portion of the retina that most likely correlated with the subretinal bleb, with only a 
minor scattering of fluorescence visible in other locations (Figure 2A; blue circle).  
 
PDE6α and RHO protein levels increased after treatment of Pde6αnmf363 mutant eyes  
Since AAV2/8-TurboRFP transduced retinal cells after a single subretinal injection, we 
tested whether AAV2/8(Y733F)-Rho-Pde6α could express PDE6α in Pde6αnmf363 mutant mice. 
In untreated mutant eyes at 2 months of age, PDE6α protein was undetectable in the retinal lysate 
(Figure 2B). In contrast, PDE6α was observed in the retinal lysate of the mutant eye treated with 
the gene therapy vector (Figure 2B). We also tested whether rhodopsin (RHO) is translated in 
the Pde6αnmf363 mutant mice, since RHO levels are indicative of the health of the photoreceptor 
outer segments (OS). The RHO protein levels were severely reduced in the untreated mutant eye, 
only detectable after over-exposure of the film, but RHO protein was detected at high levels in 
the treated mutant eye (Figure 2B). We then compared the RHO levels in the treated mutant 
eyes at 2 and 11 months of age with that of a B6 control mouse (Figure 2C). RHO is lower in 
the 2-month-old treated mutant eye, and RHO levels decline further by 11 months of age 
compared with a B6 control (Figure 2C). In summary, the untreated mutant eye expressed 
undetectable levels and low levels of PDE6α and RHO, respectively, while the AAV2/8(Y733F)-
Rho-Pde6α-treated mutant eye expressed higher levels of both PDE6α and RHO, although not as 
high as the levels of RHO in a B6 control mouse eye.  
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Figure 2. Viral spread and enhanced levels of PDE6α in treated mutant eyes. A single 
subretinal injection of AAV2/8-TurboRFP into the right eye of post-natal day (P) 5 Pde6αnmf363 
mice and visualized at P55. Red fluorescence was overlayed onto a bright-field image of the 
whole mount for localization of fluorescence in respect to the entire retina. Scale bar: 4000 µm 
(A). A single subretinal injection of AAV2/8(Y733F)-Rho-Pde6α was performed in the right eye 
of P5 Pde6αnmf363 mice. Immunoblot analyses using PDE6α, RHO and β-actin antibodies were 
performed on retinal lysates from 2-month-old mice. β-Actin was used as a loading control. 
Forty micrograms of protein was loaded for both the treated and untreated mutant eyes. PDE6α 
antibody was not specific, and cross-reacted with the highly homologous PDE6β subunit (B). 
Immunoblot analyses using RHO and β-actin antibodies were performed on retinal lysates from a 
2-month-old–treated mutant eye and a control B6 eye, along with an 11-month-old–treated 
mutant eye and control B6 eye. β-Actin was used as a loading control. Nine micrograms of 
protein was loaded for the 2-month-old samples and 20 µg of protein was loaded for the 11-
month-old samples (C). 
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Delay of retinal pigment epithelial degeneration in treated Pde6αnmf363 mutant eyes  
Since PDE6α protein is detectable after viral transduction and RHO protein levels 
suggest healthy photoreceptor neurons, we tested whether AAV2/8(Y733F)-Rho-Pde6α can 
rescue retinal pigment epithelial (RPE) degeneration visible upon fundus examination in RP 
patients. We examined infrared (IR) images of treated and fellow-untreated Pde6αnmf363 mutant 
eyes at 5, 7, 9 and 11 months of age (Figure 3). A B6 mouse IR image was shown as a control at 
8 months of age (Figure 3I). At 5 months of age, the untreated mutant eye shows the starting 
signs of RPE atrophy compared with the treated mutant eye (Figure 3A and B; asterisks). 
Beginning at 7 months of age and continuing through 11 months of age, extensive RPE atrophy 
is visible in the untreated mutant eye (Figure 3C, E and G; asterisks), while the treated mutant 
eye displays only a slight amount of RPE atrophy and appears to remain the same over time 
(Figure 3D, F and H).  
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Figure 3. Delay of RPE atrophy after AAV2/8(Y733F)-Rho-Pde6α transduction. 
Representative infrared (IR) images of an untreated Pde6αnmf363 mutant eye at 5 (A), 7 (C), 9 (E) 
and 11 (G) months of age compared with the fellow-treated Pde6αnmf363 mutant eye at 5 (B), 7 
(D), 9 (F) and 11 (H) months of age. Images for 5 and 7 months of age are taken from the same 
mouse, images from 9 and 11 months of age are taken from a second mouse for replication 
purposes. Representative IR image of a C57BL/6J control mouse at 8 months of age (I). 
Increased IR reflectance represents RPE atrophy (*). The attenuation of the arterioles is also 
arrested in the treated eyes at the ages examined. IR imaging was obtained at 790 nm absorption 
and 830 nm emission using a 55° lens. Images were taken of the central retina, with the optic 
nerve located at the center of the image and the site of the subretinal bleb along the lower left-
hand quadrant. 
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Increased PDE6α protein improved photoreceptor survival in Pde6αnmf363 mice  
Since IR images displayed reduced RPE atrophy in treated Pde6αnmf363 mutant eyes 
compared with the fellow untreated eyes for at least 11 months, we tested whether 
AAV2/8(Y733F)-Rho-Pde6α is rescuing the photoreceptors in the Pde6αnmf363 mice. We 
examined histological sections from both the untreated and treated mutant eyes (Figure 4). 
When viewing the treated retina of a 2-month-old Pde6αnmf363 mouse, the preservation of the 
photoreceptor cell bodies and OS is detectable in half of the retina (Figure 4A).  
To determine the extent and longevity of this rescue, we examined the outer nuclear layer 
(ONL) thickness of the rescued portion of the treated retina compared with both the un-rescued 
opposing side of the treated retina (as an internal control) and fellow untreated Pde6αnmf363 eyes 
in a longitudinal study (Figure 4B). There were significantly more photoreceptor nuclei in the 
rescued portion of the treated eye (3.79 ± 4.21) when compared with the untreated fellow eye 
(1.44 ± 5.46) for the 6 months examined, and the opposing side of the treated retina showed a 
similar ONL thickness to the untreated fellow eye as would be expected with little to no rescue 
(Figure 4B). The photoreceptor cell bodies declined between 1 and 2 months of age in the 
treated eye, then stabilized over the following months (Figure 4B).  
At 5 months of age, the ONL in mutant eyes was undetectable compared with a B6 
control eye (Figure 4C and E). In contrast, the ONL was not only detectable in the treated 
mutant eye compared with the untreated mutant eye (Figure 4C and D), but it was ∼50% of the 
ONL thickness of the control B6 eye (Figure 4D and E). Furthermore, OS were preserved in the 
treated regions of the mutant eye (Figure 4D) compared with the untreated mutant eye 
(Figure 4C), and of similar length as the B6 control (Figure 4E). Thus, photoreceptors are 
present in the treated mutant eyes at a time when there is a loss of photoreceptors in the untreated 
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mutant eyes, and this significant improvement in photoreceptor survival persists through at least 
6 months of age.  
 
 
Figure 4. Improved photoreceptor survival after AAV2/8(Y733F)-Rho-Pde6α transduction. 
H&E stained retinal section of a 2-month-old-treated Pde6αnmf363 mouse eye (A). Images were 
composited together to show entire retina. Arrows show ONL and OS regions. Scale bar: 1000 
µm. Quantification of the thickness of the ONL by counting the columns of photoreceptor nuclei 
in the rescued half of the treated retina, the un-rescued half of the treated retina (labeled internal 
control) and fellow-untreated eyes from 1 to 6 months of age (B). Error bars show SEM for each 
time point and the significance was calculated for the rescued half of the treated retina compared 
with the untreated fellow eyes using ratio paired t-test analysis. N ≥ 3 mice. H&E stained retinal 
section of a 5-month-old-untreated Pde6αnmf363 mouse retina (C), the fellow Pde6αnmf363 mouse 
retina treated with AAV2/8(Y733F)-Rho-Pde6α (D) and a B6 control mouse (E). Scale bar: 600 
µm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; OS, outer 
segments; RPE, retinal pigment epithelium. *p < 0.05; **p < 0.01; ***p < 0.001.  
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Despite focal rescue of retinal structure adjacent to the injection site, global functional 
rescue is observed in Pde6αnmf363 mice  
Since mutant photoreceptors survived after AAV2/8(Y733F)-Rho-Pde6α transduction, 
we tested whether these rescued photoreceptor cells were functional. We measured 
electroretinogram (ERG) responses in Pde6αnmf363 mice after AAV2/8(Y733F)-Rho-Pde6α 
transduction beginning at 1 month of age (Figure 5). By 2 months of age when the untreated 
mutant eye lost almost all visual response, the treated mutant eye retained a strong visual 
response, although with a lower maximum b-wave amplitude and reduced a-wave amplitude 
than that of a control wild-type B6 mouse (Figure 5A). At 5 months of age, the treated mutant 
eye retained an ∼100 µV b-wave amplitude, similar to that observed at 2 months of age 
(Figure 5B). Each month, the overall visual response was significantly enhanced in the treated 
eyes compared with untreated fellow eyes and this lasted through 9 months of age, the last age 
examined (Figure 5C). 
Furthermore, since recessive RP caused by mutations in PDE6α is a rod-cone dystrophic 
disease, we tested whether the rod- and cone-specific visual responses were improved after a 
single subretinal injection with AAV2/8(Y733F)-Rho-Pde6α. The maximum ERG a-wave, 
which is a photoreceptor-dominated response, although substantially decreased in the ERG traces 
(Figure 5A and B), was increased in our treated mutant eyes compared with fellow untreated 
eyes over the 9-month period (Figure 5D). Additionally, ERG responses from a dim light rod-
only stimulation showed some waveforms where, at 5 months of age, the treated mutant eye 
retained a strong rod response, although with a lower maximum amplitude than that of a control 
wild-type B6 mouse (Figure 5E). However, not all treated mice displayed a strong dim light 
ERG trace, and between 2 and 5 months of age, the treated mutant eyes showed improved rod-
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specific b-wave responses over the fellow untreated mutant eyes, but these were not significant 
(Figure 5G).  
Lastly, even if only a relatively small number of rod photoreceptor cells were functional 
after treatment, cone cells may still survive and function in these mice, so we tested for cone 
cell-specific visual function. We used light-adapted photopic ERG responses, which are cone-
specific, and found that at 5 months of age, the traces from the treated mutant mice displayed a 
strong cone cell visual response compared with the untreated eye, which lost almost all visual 
response (Figure 5F). Additionally, the waveforms from the treated mutant eye were similar to 
that of a B6 control mouse, and only slightly reduced in amplitude (Figure 5F). The cone cell 
visual responses were enhanced in our treated mutant eyes compared with untreated fellow eyes 
through at least 9 months of age, the last date tested (Figure 5H). Taken together, our data 
suggest that treatment with AAV2/8(Y733F)-Rho-Pde6α, and its subsequent increase of PDE6α 
levels, rescues photoreceptor survival and inner retina visual function for at least 9 months in the 
Pde6αnmf363 mouse.  
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Figure 5. Rescued visual function after AAV2/8(Y733F)-Rho-Pde6α transduction. 
Representative scotopic maximum ERG traces for a B6 control mouse (black), the treated eye 
(dark grey) and the untreated eye (light grey) of a Pde6αnmf363 mouse at 2 months of age (A), and 
5 months of age (B). Maximum scotopic b-wave amplitudes in a B6 mouse, the treated 
Pde6αnmf363 eyes and fellow-untreated eyes monthly between 1 and 9 months of age (C). 
Maximum scotopic photoreceptor-mediated a-wave amplitudes (shown as positive values) in a 
B6 mouse, the treated Pde6αnmf363 eyes and fellow-untreated eyes monthly between 1 and 9 
months of age (D). Representative scotopic dim light rod-specific ERG traces of a B6 control 
mouse (black), the treated eye (dark grey) and the untreated eye (light grey) of a Pde6αnmf363 
mouse at 5 months of age (E), and representative photopic single flash cone-mediated ERG 
traces for a B6 control mouse (black), the treated eye (dark grey) and the untreated eye (light 
grey) of a Pde6αnmf363 mouse at 5 months of age (F). Dim light rod-specific scotopic b-wave 
amplitudes in a B6 mouse, the treated Pde6αnmf363 eyes and fellow-untreated eyes monthly 
between one and 9 months of age (G). Photopic cone-specific b-wave amplitudes in a B6 mouse, 
the treated Pde6αnmf363 eyes and fellow-untreated eyes from 3 to 9 months of age (H). B6 mouse 
ERG results did not vary over the 6-month testing period so only the first and last results are 
shown in the charts. Error bars show SEM for each time point and the significance was 
calculated using the ratio paired t-test analysis. N≥ 3 mice. *p < 0.05; **p < 0.01; ***p < 0.001.  
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We also tested if injection of the viral vector alone is able to cause a functional 
restoration of the photoreceptor cells. We analyzed ERG responses from the AAV2/8-TurboRFP 
treated Pde6αnmf363 mice, to ensure that the injection of the AAV2/8 virus alone does not cause 
any functional rescue effect (Figure 6). At 6 weeks of age, the photoreceptor-specific and overall 
visual function in the AAV2/8-TurboRFP treated and untreated eyes were not significantly 
different (Figure 6). In contrast, the AAV2/8(Y733F)-Rho-Pde6α treated mutant eyes displayed 
significant improvement over the untreated eyes or those treated with the AAV2/8-TurboRFP 
virus alone (Figure 6). Thus, the AAV2/8(Y733F)-Rho-Pde6α vector-induced increase in 
PDE6α protein is likely responsible for the significant rescue in visual function through 9 months 
of age (Figures 3–5). 
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Figure 6. No rescued visual function from a control vector injection. Maximum 
photoreceptor-specific a-wave amplitudes (shown as positive values) in 6-week-old treated 
Pde6αnmf363 eyes compared with their fellow-untreated eyes and Pde6αnmf363 mice treated with 
AAV2/8-TurboRFP alone (A). Maximum b-wave amplitudes in 6-week-old-treated Pde6αnmf363 
eyes compared with their fellow-untreated eyes and Pde6αnmf363 mice treated with AAV2/8-
TurboRFP alone (B). Error bars show SEM for each time point and the significance was 
calculated using ratio paired and two-tailed t-test analyses. N≥ 8 mice. *p < 0.05; **p < 0.01; 
***p < 0.001.  
 
DISCUSSION  
Only recently, attempts at using AAV2/8 gene therapy to functionally rescue mouse 
models of RP, in particular one Pde6β mouse model, has shown long-term rescue effects (85). 
Lentiviral, or other AAV serotypes, can delay photoreceptor degeneration in multiple Pde6β 
mouse models, but long-term efficacy has not been found in the majority of the reported studies 
(124-131). Although one AAV gene therapy case has now shown 6-month rescue in a slower 
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photoreceptor degeneration Pde6β mouse model, studies have not been conducted on animal 
models with mutations in the α-subunit of PDE6 to ameliorate the disease progression.  
Here, we applied AAV-based gene therapy that can rescue photoreceptor degeneration 
and restore neuronal function in a Pde6αnmf363 mouse model of recessive RP. We demonstrate 
that after a single subretinal injection of AAV2/8(Y733F)-Rho-Pde6α into the Pde6αnmf363 
mouse, the phenotype can be both structurally and functionally rescued. Sakamoto et al. showed 
that PDE6α protein was severely diminished in P12 Pde6αnmf363 mutant mice (121), and we 
found that PDE6α protein was undetectable in the 2-month-old Pde6αnmf363 mutant retinal 
lysates. This suggests that the PDE6α protein levels found in the treated mutant eye most likely 
came from the cells that were transduced by the AAV2/8(Y733F)-Rho-Pde6α vector. 
Additionally, the small amount of PDE6α protein provided by the viral injection protected the 
RHO protein expression in the treated Pde6αnmf363 mutant eye, since it was undetectable in the 
untreated mutant eye. Thus, AAV2/8(Y733F)-Rho-Pde6α partially rescues mutant 
photoreceptors in treated eyes as evidenced by the increase in both PDE6α levels, directly, and 
RHO levels, indirectly, both of which are necessary to correct the recessive RP disease 
phenotype in our Pde6αnmf363 mouse model.  
Effective photoreceptor rescue after AAV2/8(Y733F)-Rho-Pde6α transduction is 
confined to the location of the subretinal bleb, and the variability of the size of the subretinal 
bleb can account for gene transfer and therapeutic efficiency between different eyes. 
Photoreceptor survival occurred along one half of the treated retina (Figure 4), most likely on 
the side where the gene therapy injection site was located and the subretinal bleb was formed 
(Figure 2A). This correlates with the ERG results, where the treated Pde6αnmf363 mutant mice 
had enhanced visual responses long-term, at ∼20% of that found in a B6 mouse (Figure 5).  
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Additionally, the amount of cells that are transduced by the virus is variable. The 
representative ERG waveforms (Figure 5A, B, E and F) display the ERG responses under each 
condition in a mouse with a strong visual response. The charts shown in Figure 5C, D, G and H 
take into account all of the mice at each time examined, and this variation in the size of the 
subretinal bleb during the surgical procedure may account for the strength of significance and 
deviation in these charts.  
For the dim light rod-specific ERG responses, statistical analysis of the treated and 
untreated eyes demonstrated no significant differences except at 9 months of age in this pooled 
set of treated eyes (N ranges from 3–8 mice per time point), although the treated mutant eyes 
showed some improvement over the untreated mutant eyes from 2 to 9 months of age. 
Additionally, we found three mice with evidence of rod-specific ERG responses much higher 
than the untreated eyes (Figure 5E), and these three mice showed comparable rod-specific ERG 
responses at multiple time points in the 9-month study period. One interpretation of this result is 
that a threshold level of transduction (number of rods transduced) is able to produce a more 
effective rescue of rod function and that the transduction levels of the majority of mice were 
below this level. This is likely due to variation during the surgical procedure. Alternatively, the 
variable ability of the vector to produce detectable rod-specific ERG rescue may be related to the 
capability of the vector to sustain PDE6α expression and/or survival of the transduced rods.  
Additionally, we found that the ONL and the OS declined in the treated eyes until 2 
months of age, and then remained at a similar thickness through 6 months of age. This suggests a 
halt in the progression of photoreceptor death after transduction with AAV2/8(Y733F)-Rho-
Pde6α, where the treated eye has photoreceptor survival in the location of the subretinal bleb, but 
the remaining half of the retina continues to degenerate. This effect was also seen in the ERG 
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results, where ERG traces decline until 2 months of age, then have a similar visual response to 
those at 9 months of age in the same mouse (Figure 4D and E, Figure 5A and B). At 2 months 
of age, the ERG tracing for the treated mutant eye has a similar maximum b-wave amplitude to 
that of a control B6 mouse; however, a decreased a-wave amplitude as would be expected with 
the loss of photoreceptor cells in the unrescued half of the treated retina. The strength of the b-
wave amplitude is likely due to the remaining photoreceptors and the inner retinal cells of the 
eye. By 5 months of age, the ERG tracing for the treated mutant eye retains the strong visual 
response from the remaining photoreceptors and inner retinal cells, but has a reduced maximum 
b-wave amplitude compared with the B6 control mouse response, which correlates with the 
thinner ONL seen in Figure 4D compared with Figure 4E, as the unrescued half of the treated 
retina is fully degenerated.  
However, despite focal rescue of retinal structure adjacent to the injection site, we 
achieved remarkable global functional restoration as assessed by ERG that lasted over 9 months 
of age, half of the mouse lifespan. RHO levels declined by 11 months of age in the treated 
mutant eyes; however, IR imaging showed strong RPE atrophy in untreated mutant eyes, but 
healthy fundus images of the fellow treated mutant eyes through 11 months of age; half of the 
mouse lifespan. Although only half of the retina retains photoreceptor cells after subretinal 
injection, it appears that these cells are enough to protect the treated eye from the secondary 
remodeling effects that occur after photoreceptor cell death in RP, such as RPE atrophy.  
‘Sham’ injections have been found to produce rescue effects that last through a 6-month 
testing period in the Royal College of Surgeons (RCS) rat model of RP (148-149). In RCS rats, a 
washing away of accumulated OS debris during the injection procedure is the likely cause of the 
noticeable rescue effects. Injection of our AAV2/8 ‘blank’ vector alone did not cause functional 
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rescue in the Pde6a
nmf363
 mouse model; therefore, the rescue effects found for 9 months in this 
study are specific to AAV2/8(Y733F)-Rho-Pde6α transgene transduction.  
Early rod photoreceptor dysfunction characterizes diseases that include RP and AMD. 
The reduction of PDE6 function is a common denominator in 36 000 cases of photoreceptor 
degeneration. Our study indicates that it may be possible to develop treatments based on 
correcting PDE6 levels using gene therapy vectors. Additional studies, however, are needed to 
examine the full duration of rescue, the timing of injections in respect to disease progression, the 
possibility of multiple injection sites, and re-injections if the virus begins to lose its ability to 
rescue the cells. While these studies need to be conducted, our results indicate a significant 
treatment potential for both photoreceptor cell survival and functional rescue in mice carrying a 
mutant allele of Pde6α. Ultimately, the results from this study demonstrates potential for using 
gene therapy modifications to treat RP in the Cardigan Welsh Corgi, a dog model with a 
mutation in PDE6α, and in human patients with RP caused by PDE6α mutations.  
 
MATERIALS AND METHODS 
Mouse lines and husbandry 
C57BL/6J-Pde6αnmf363/nmf363, with a D670G mutation, herein referred to as Pde6αnmf363, 
mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Mice were maintained 
in the Columbia University Pathogen-free Eye Institute Annex Animal Care Services Facility 
under a 12/12-h light/dark cycle. All experiments were approved by the local Institutional 
Animal Care and Use Committee (IACUC) under protocol #AAAB-4306. Mice were used in 
accordance with the Statement for the Use of Animals in Ophthalmic and Vision Research of the 
Association for Research in Vision and Ophthalmology, as well as the Policy for the Use of 
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Animals in Neuroscience Research of the Society for Neuroscience. Pde6αnmf363 mice used in 
this study were bred from a colony of mice that has been previously reported (121). Pde6αnmf363 
are coisogenic in the C57BL/6J (B6) background; therefore, age-matched B6 mice were used as 
experimental controls (The Jackson Laboratory).  
 
Construction of AAV vectors 
AAV serotype 2/8 capsids containing a point mutation in surface-exposed tyrosine 
residues, AAV2/8(Y733F), exhibit higher transduction efficiency in photoreceptors and a faster 
onset of expression than other AAV serotypes when delivered into the subretinal space of the eye 
(85). Therefore, these vectors were used for packaging our Pde6α construct. Vector plasmids 
were constructed by inserting 1.1 kb of the murine rhodopsin promoter region [Ensembl, 
rhodopsin, chromosome 6: (115, 930, 881–115, 931, 988); Ensembl, rhodopsin, ATG = 1: 
(−1125, −17)] and a full-length murine Pde6α cDNA fragment into the pZac2.1 plasmid to 
generate pZac2.1.mRhodopsin.mPde6α.SV40 (150). AAV vectors were created, packaged and 
purified at the Penn Vector Corporation, to become 
AAV2/8(Y733F).mRhodopsin.mPde6α.SV40 (University of Pennsylvania, PA, USA). The 
AAV2/8(Y733F).mRhodopsin.mPde6α.SV40 vector will be referred to as AAV2/8(Y733F)-
Rho-Pde6α in this publication. AAV2/8.CMV.TurboRFP.RBG was purchased from the Penn 
Vector Corporation as the AAV serotype control and will be referred to as AAV2/8-TurboRFP 
in this publication.  
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Transduction of AAV vectors 
To increase levels of wild-type PDE6α, we injected AAV2/8(Y733F)-Rho-Pde6α (0.7µl, 
1.26e13 genome copy (GC)/ml) into the subretinal space of the right eye of Pde6αnmf363 mice at 
post-natal day (P) 5. AAV2/8-TurboRFP (0.7 µl, 7.28e12 GC/ml) was injected into the 
subretinal space of the right eye of Pde6αnmf363 mice at P5 for control experiments. Virus 
particles were injected at the 6 o'clock position of the eye, ∼1.5 mm from the limbus, to produce 
a subretinal bleb in the mid-periphery of the retina. The left eyes of all mice were kept as a 
matched control for experimental analyses. Anesthesia and surgery were performed as previously 
described (125).  
 
Whole mount analysis 
Mice were euthanized according to the established IACUC guidelines. Eyes were 
enucleated and placed in 2% paraformaldehyde for 1 h at room temperature. The optic nerve, 
cornea and lens were removed. The whole eyecup was then flattened by means of four radial cuts 
extending out from the optic nerve and mounted with mounting medium (Vectashield, 
Burlingame, CA, USA). RFP visualization was achieved by fluorescence microscopy, and 
bright-field imaging was used to visualize the whole retina (Leica DM 5000B microscope). 
Pictures were taken at 2.5× magnification using the Leica Application Suite Software (Leica 
Microsystems Inc., Germany).  
 
Immunoblot analysis 
Retinas were homogenized in 10% sodium dodecyl sulfate (SDS) by brief sonication and 
denatured at 100°C for 5 min. Following centrifugation, the total protein content per sample was 
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measured using the DC protein assay method (Bio-Rad Laboratories, Hercules, CA, USA). 
Proteins were separated by SDS polyacrylamide gel electrophoresis. The samples were then 
transferred to nitrocellulose membranes, which were blocked in 3% bovine serum albumin 
(BSA; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 150 mmol/l NaCl, 100 mmol/l Tris 
(pH 7.4) and 0.5% Tween-20 (BSA-TTBS). Membranes were incubated with either anti-PDE6α 
(1:300, Abcam), rhodopsin (1D4) (1:500, Santa Cruz) or rabbit anti-cytoskeletal actin (1:300, 
Bethyl) antibodies in BSA-TTBS. After washing in TTBS, filters were incubated with goat anti-
rabbit or goat anti-mouse-conjugated horseradish peroxidase secondary antibodies (1:20 000, 
Santa Cruz Biotechnology). After washing, antibody complexes were visualized by a 
chemiluminescence detection kit (Immobilon Western, Millipore Corporation, Billerica, MA, 
USA) and a Kodak BioMax film (Kodak, Rochester, NY, USA).  
 
Infrared Imaging 
IR fundus imaging was obtained with the Spectralis scanning laser confocal 
ophthalmoscope (Heidelberg Engineering, Carlsbad, CA, USA). IR imaging was obtained at 790 
nm absorption and 830 nm emission using a 55° lens. Images were taken of the central retina, 
with the optic nerve located in the center of the image and the site of the subretinal bleb along 
the lower left-hand quadrant.  
 
Histochemical analyses 
Mice were sacrificed and the eyes enucleated as previously described (133). Excalibur 
Pathology, Inc. prepared Hematoxylin & Eosin retinal sections. The morphology of 
photoreceptors and the amount of photoreceptor cell nuclei of AAV2/8(Y733F)-Rho-Pde6α-
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treated eyes were compared with the untreated fellow eyes. Quantification of photoreceptor 
nuclei was conducted on several sections that contained the optic nerve, as follows: the distance 
between the optic nerve and the ciliary body was divided into four, approximately equal, 
quadrants. Three columns of nuclei (how many cell nuclei thick) were counted within each 
single quadrant. These counts were then used to determine the average thickness of the ONL for 
each individual animal at each time. For the treated eyes, the rescued half of the treated retina 
between the optic nerve and the ciliary body was quantified in this manner, with the opposite 
side of the retina, between the optic nerve and the ciliary body, being quantified similarly and 
considered the unrescued half of the treated mutant eye (the internal control). Averages and 
standard deviations were calculated from animals for each time point using ratio paired t-test 
statistical analyses with statistical significance set at P < 0.05. Sectioning proceeded along the 
long axis of the segment, so that each section contained upper and lower retina as well as the 
posterior pole. 
 
Electroretinograms 
Mice were dark-adapted overnight, manipulations were conducted under dim red light 
illumination, and recordings were made using Espion ERG Diagnosys equipment (Diagnosys 
LLL, Littleton, MA, USA). Adult B6 control mice were tested at the beginning of each session to 
ensure equal readouts from the electrodes for both eyes before testing the experimental mice. 
Pupils were dilated using topical 2.5% phenylephrine hydrochloride and 1% tropicamide (Akorn 
Inc., Lakeforest, IL, USA). Mice were anesthetized by intraperitoneal injection of 0.1 ml/10 g 
body weight of anesthesia [1 ml ketamine 100 mg/ml (Ketaset III, Fort Dodge, IA, USA) and 0.1 
ml xylazine 20 mg/ml (Lloyd Laboratories, Shenandoah, IA, USA) in 8.9 ml PBS]. Body 
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temperature was maintained at 37°C using a heating pad during the procedure. Hand-made 
electrodes were placed upon the corneas and gonioscopic prism solution (Alcon Labs, Inc., Fort 
Worth, TX, USA) was applied to each eye. Both eyes were recorded simultaneously. A total of 
40–60 responses were averaged for each trial. All further detail on the ERG method has been 
described previously (134-135). We measured scotopic dim light maximal b-wave ERG 
responses to assess rod-only responses, scotopic maximal b-wave ERG responses to assess inner 
retina function, scotopic maximal a-wave ERG responses to assess photoreceptor-specific 
function, and photopic maximal b-wave ERG responses to assess cone-specific function. 
Maximal responses were taken from the Espion readout in microvolts and quantified using ratio 
paired t-test statistical analyses with statistical significance set at P < 0.05.  
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Chapter 5: Mid-stage intervention achieves similar efficacy as conventional early-stage 
treatment using gene therapy in a pre-clinical model of retinitis pigmentosa***** 
***** This chapter is currently in press for publication: Wert, K.J., Sancho-Pelluz, J. and 
Tsang, S.H. (2013) Mid-stage intervention achieves similar efficacy as conventional early-
stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa. Hum. 
Mol. Genet. DOI: ddt452. 
 
ABSTRACT 
Deficiencies in rod-specific cyclic guanosine monophosphate (cGMP) 
phosphodiesterase-6 (PDE6) are the third most common cause of autosomal recessive retinitis 
pigmentosa (RP). Previously, viral gene therapy approaches on pre-clinical models with 
mutations in PDE6 have demonstrated that the photoreceptor cell survival and visual function 
can be rescued when the gene therapy virus is delivered into the subretinal space before the onset 
of disease. However, no studies have currently been published that analyze rescue effects after 
disease onset, a time when human RP patients are diagnosed by a clinician and would receive the 
treatment. We utilized the AAV2/8(Y733F)-Rho-Pde6α gene therapy virus and injected it into a 
pre-clinical model of RP with a mutation within the alpha subunit of PDE6; Pde6αD670G. These 
mice were previously shown to have long-term photoreceptor cell rescue when this gene therapy 
virus was delivered before the onset of disease. Now, we have determined that subretinal 
transduction of this rod-specific transgene at post-natal day (P) 21, when approximately half of 
the photoreceptor cells have undergone degeneration, is more efficient in rescuing cone than rod  
photoreceptor function long-term. Therefore, AAV2/8(Y733F)-Rho-Pde6α is an effective gene 
therapy treatment that can be utilized in the clinical setting, in human patients who have lost 
portions of their peripheral visual field and are in the mid-stage of disease when they first present 
to an eye-care professional. 
96 
 
 
INTRODUCTION 
Retinitis pigmentosa (RP) is the most common cause of hereditary blindness worldwide, 
and mutations within the rod-specific cyclic guanosine monophosphate (cGMP) 
phosphodiesterase 6 (PDE6) is the third most common cause of autosomal recessive RP (42, 45, 
54, 122). The early clinical symptoms of this disease include night blindness, rod cell 
degeneration, and secondary cone cell death (147-149, 151). There are several mouse models 
with mutations in the beta subunit of PDE6 that have been utilized for studying gene therapy for 
RP, and only one published manuscript for gene therapy in a mouse model with a mutation in the 
alpha subunit of PDE6 (84-85, 124-125, 131, 144, 152). Recently, with advances in gene 
therapy, such as the use of the AAV2/8(Y733F) virus to efficiently transduce the photoreceptor 
cells, long-term rescue effects have been proven for two mouse models of RP caused by 
mutations within PDE6, one with the mutation in the beta subunit of PDE6, and the other with a 
mutation in the alpha subunit of PDE6 (85, 152). 
For several reasons, these gene therapy studies have been conducted by delivering the 
virus before the onset of degeneration in the pre-clinical model. This allows for the greatest 
efficacy of the gene therapy virus to be shown in order to prove it is effective for RP treatment. 
Additionally, cryoanesthesia can be used for young mice, which is a safer alternative to 
ketamine/xylazine or isoflurane anesthetics (153). Lastly, the transduction of the gene therapy 
virus has been found to be limited to the location and size of the subretinal bleb during the 
surgical procedure (152). The maturation of the subretinal extracellular matrix in older mice can 
block viral spread after subretinal injection, limiting the rescue effect to a smaller number of 
transduced cells (154-156). Now that gene therapy viruses have proven to have long-term rescue 
effects in mouse models with PDE6 deficiencies when delivered prior to the onset of 
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photoreceptor degeneration, it will be important to study whether or not these gene therapy 
viruses can promote cell survival and rescue visual function when delivered after the onset of 
disease. 
Human patients with retinal dystrophic diseases, such as RP, may not be diagnosed by a 
clinician until they have mid-stage disease. This includes the loss of their peripheral visual field, 
when rod photoreceptor cells have already begun to degenerate. A recent publication studying 
both human patients and canine models of Leber congenital amaurosis (LCA) after subretinal 
injection of an AAV2-CMV-RPE65 virus indicated that despite functional rescue of vision, the 
photoreceptor cells continue to degenerate at the same rate (157). This would suggest that gene 
therapy treatment after the onset of disease may not be effective for use in human clinical trials. 
Only two studies have been published that examined the effects of gene therapy delivered 
after disease onset (158-159). The first study tested AAV5 gene therapy in a murine model of 
LCA, caused by a mutation in the retinal pigment epithelium (RPE)-specific gene. This study 
was able to provide restoration of cone function using gene therapy vector after disease onset. 
The second study provided AAV5 gene therapy to a canine model of achromatopsia caused by a 
mutation within the beta subunit of the cyclic nucleotide-gated photoreceptor channels (CNGB3).  
However, gene therapy delivered after disease onset to this cone-specific mutation was unable to 
restore function unless the vector was delivered in combination with ciliary neurotrophic factor 
(CNTF).  
Therefore, we tested whether it is feasible to restore both rod and cone cell function in the 
Pde6α mutant mice, as no studies have shown cone restoration in models with mutations within 
the rod photoreceptors. We proposed to transduce our previously utilized AAV2/8(Y733F)-Rho-
Pde6α gene therapy virus in the Pde6αD670G mutant mouse model after the onset of photoreceptor 
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degeneration. This AAV2/8(Y733F) gene therapy vector has been shown to be more effective in 
photoreceptor cell transduction than the AAV5 serotype (160). Additionally, this mouse model 
was shown to have long-term rescue of the photoreceptor cell nuclei, visual function, and 
prevention of the secondary migration of the retinal pigment epithelium (RPE) when the gene 
therapy virus was delivered at post-natal day (P) 5, before the disease onset (152). We utilized 
the same mouse model and gene therapy vector, but transduced the virus into the subretinal space 
at P21, after approximately half of the photoreceptor cells in the eye have undergone 
degeneration. We compared results from gene therapy treatment in this pre-clinical model of RP 
before the disease onset to treatment using the same vector in the same model during mid-stage 
of disease (i.e., after the loss of approximately half of the photoreceptor cells).We found that 
even when the gene therapy virus is delivered at mid-stage of disease (i.e., after the onset of 
disease), we can promote photoreceptor cell survival and a rescue of visual function long-term in 
the pre-clinical model of RP. 
 
RESULTS  
AAV2/8(Y733F)-Rho-Pde6α delivery at approximate time of human diagnosis 
 Human RP patients typically present to an eye care professional after loss of their 
peripheral visual field, suggesting a mid-stage of RP disease where rod photoreceptors have 
already begun to undergo degeneration. We gave a single subretinal injection of 
AAV2/8(Y733F)-Rho-Pde6α into the right eyes of the Pde6αD670G mice at post-natal (P) day 21. 
This corresponds to mid-stage of RP in the Pde6αD670G mice, as seen in a longitudinal 
histological analysis from P12 to P30 (Figure 1A). At the time of injection, P21, the mice have 
lost approximately half of their photoreceptor outer nuclear layer (ONL) thickness. Expression of 
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the transgene and protein of interest, PDE6α, will occur by P24 in the already diseased retina, 
when further loss of the photoreceptor cells has continued after delivery of the AAV virus.  
 Subretinal injections of AAV2/8(Y733F)-Rho-Pde6α at P5, as previously studied in the 
Pde6αD670G mutant mouse model (152), occurred before the full development of the extracellular 
matrix of the eye. To determine that the transduction efficiency of AAV2/8(Y733F) within the 
retina is the same at both P5 and P21, and not lessened by the developed extracellular matrix, we 
administered a subretinal injection of AAV2/8(Y733F)-TurboRFP to a litter of homozygous 
Pde6αD670G mutant mice at P21. This vector will express red fluorescent protein (RFP), which 
allows for the visualization of the cells transduced by the virus. After a single subretinal injection 
at P21, RFP expression remained visible within the retina at 2 months of age, indicating that the 
virus was taken up by the retinal cells and survived for at least 5 weeks post-injection (Figure 
1B). As expected, RFP expression was detected within the portion of the retina that most likely 
correlated with the subretinal bleb,  but was found to be similar in size and expression to that of 
the subretinal bleb after gene therapy delivery at P5, affecting approximately 20-30% of the 
retina (Figure 1B; blue circle; 152). 
 
AAV2/8(Y733F)-Rho-Pde6α does not induce an inflammatory reaction in Pde6αD670G mice 
 The continual expression of RFP after a single subretinal injection of AAV2/8(Y733F)-
TurboRFP at P21 suggests that the AAV2/8(Y733F)-Rho-Pde6α will be able to survive within 
the diseased retina and express PDE6α. However, one main concern when this gene therapy 
approach is studied is the potential for antibody production in the host after transduction of the 
AAV2/8(Y733F) virus. We collected serum from 5 transduced Pde6αD670G mice and 5 untreated 
Pde6αD670G mice at 2 months of age. We then used this serum on a western blot to test for 
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antibodies against PDE6α in a C57BL/6J (B6) mouse retina. Both the serum from the Pde6αD670G 
mouse transduced with the gene therapy vector (treated lane) and the serum from an untreated 
Pde6αD670G mouse (untreated lane) did not react against PDE6α in the B6 retinal lysate (Figure 
1C). In contrast, a commercial PDE6α antibody was able to detect the presence of the PDE6αβ 
complex from the same B6 retinal lysate on the western blot gel (control lane). Beta-actin was 
used as a loading control to confirm the presence of the B6 retinal lysate at similar levels for 
each lane. Therefore, no antigens were produced 1 month after injection with the 
AAV2/8(Y733F)-Rho-Pde6α virus in the Pde6αD670G mouse. 
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Figure 1. Viral spread and lack of immune response in late-degeneration treated mutant 
eyes. A single subretinal injection of the AAV2/8(Y733F)-Rho-Pde6α was delivered at post-
natal (P) day 21, in mid-stage photoreceptor neurodegeneration as matches human patients at the 
time of diagnosis. Scale bar: 600µm. (A). A single subretinal injection of AAV2/8-TurboRFP 
into the right eye of P21 Pde6αD670G mice and visualized at P55. Red fluorescence was overlayed 
onto a bright-field image of the whole mount for localization of fluorescence in respect to the 
entire retina. Scale bar: 4000 µm (B). Immunoblot analysis for antibodies against PDE6α and β-
Actin on retinal lysates from a B6 mouse retina. Nine micrograms of B6 retinal lysate was 
loaded per lane, and lanes were incubated with blood serum from a Pde6αD670G mouse 1 month 
after a single subretinal injection of AAV2/8(Y733F)-Rho-Pde6α (treated lane), blood serum 
from an untreated Pde6αD670G mouse (untreated lane), and commercial anti-PDE6α (control 
lane). β-Actin was used as a loading control. PDE6α antibody was not specific, and cross-reacted 
with the highly homologous PDE6β subunit. N = 5 mice (C). 
 
Despite gene delivery after disease onset, increased PDE6α protein improved photoreceptor 
survival in Pde6αD670G mice  
 Since AAV2/8(Y733F)-Rho-Pde6α virus delivery at P21 does not cause antigen 
production and may protect the photoreceptor cells in the diseased retina, we examined 
histological sections from both treated and untreated Pde6αD670G mutant eyes in a longitudinal 
study and compared these to injections of the gene therapy virus at P5, before and after disease 
onset. As expected, the untreated Pde6αD670G fellow eye had no detectable photoreceptor cells 
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remaining at 6 months of age (Figure 2A). In contrast, the P21 treated Pde6αD670G eyes (Figure 
2B) displayed photoreceptor cell survival, at a similar thickness to the ONL of P5 treated 
Pde6αD670G eyes (Figure 2C). The ONL thickness of the P21 treated Pde6αD670G eyes was 
approximately 1-2 cell layers less than the P5 treated eyes, consistent with the degeneration 
between P5 and P21 before the delivery of the gene therapy virus (Figure 2B-C). In comparison 
to a wild-type B6 mouse, P21 treated Pde6αD670G eyes had an approximate 60-70% loss of the 
ONL layer and IS/OS (Figure 2D).  
 The rescue at 6 months of age in the Pde6αD670G treated eyes suggested that gene therapy 
delivery may halt the degeneration in transduced cells at the time the wild-type PDE6α protein is 
expressed by the virus. To determine the extent of this rescue, we quantified the thickness of the 
ONL of the rescued portion of the treated retina compared with both the un-rescued opposing 
side of the treated retina that did not receive the subretinal bleb (as an internal control), and the 
fellow untreated Pde6αD670G eyes from 3 to 6 months of age, when photoreceptor cells would 
typically undergo full photoreceptor neurodegeneration in the mutant Pde6αD670G mice (Figure 
2E).  
Compared to a B6 mouse control, there is an approximate 60% loss of the photoreceptor 
cell ONL thickness by 3 months of age in the P21 treated eyes, as would be expected when the 
gene therapy is delivered after the onset of photoreceptor degeneration. However, there is 
significantly more photoreceptor cells surviving in the retinas treated with the gene therapy virus 
than in the untreated fellow eye at both 3 and 6 months of age, a quarter of the mouse lifespan 
(Figure 2E). Additionally, this photoreceptor cell survival in the P21 treated mutant eyes is 
similar to the cell survival in the P5 treated mutant eyes, suggesting that the diseased retina does 
not hinder the effectiveness of the gene therapy virus (Figure 2E). The opposing side of the 
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treated retinas, which did not receive the subretinal bleb, showed a similar ONL thickness to the 
untreated fellow eye, with all photoreceptor cells degenerating by 4 months of age, as would be 
expected with little to no rescue (Figure 2E).  
Additionally, although there was increased variability in the photoreceptor cell survival 
when the gene therapy virus is delivered after the onset of degeneration, there is a stable number 
of photoreceptor cells surviving over the 3-6 month testing period, at approximately 60-70% of 
the ONL thickness of a healthy wild-type B6 retina (Figure 2E). Thus, at 6 months of age, the 
untreated Pde6αD670G eyes had no detectable photoreceptor cells while the treated fellow eyes 
had significant photoreceptor cell survival even when the gene therapy virus is delivered to a 
degenerating retina. 
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Figure 2. Improved photoreceptor survival after AAV2/8(Y733F)-Rho-Pde6α transduction 
at mid-stage of disease. H&E stained retinal section of an untreated Pde6αD670G mouse retina 
(A), the fellow P21 treated Pde6αD670G mouse retina (B), a P5 treated Pde6αD670G mouse retina 
(C) and B6 control mouse (D) at 6 months of age. Scale bar: 600µm. GCL, ganglion cell layer; 
INL, inner nuclear layer; ONL, outer nuclear layer; IS, inner segments; OS, outer segments; 
RPE, retinal pigment epithelium. Quantification of the thickness of the ONL by counting the 
columns of photoreceptor nuclei in the rescued half of the treated retina, the un-rescued half of 
the treated retina (labeled internal control) and fellow-untreated eyes from 3 to 6 months of age 
(E). Error bars show SEM for each time point and the significance was calculated for the rescued 
half of the P21 treated retina compared with the untreated fellow eyes using paired t-test 
analysis. N ≥ 3 mice. **p < 0.01. 
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Despite gene delivery after disease onset, global functional rescue is observed in Pde6αD670G 
mice  
 Since the Pde6αD670G mutant photoreceptors survived after AAV2/8(Y733F)-Rho-Pde6α 
transduction, even in a degenerating retina, we tested whether these remaining, rescued 
photoreceptor cells were functional. We measured electroretinogram (ERG) recordings in the 
Pde6αD670G mice after a single subretinal injection of AAV2/8(Y733F)-Rho-Pde6α at P21 and 
compared them to a wild-type B6 mouse, P5 treated Pde6αD670G mice, and the untreated 
Pde6αD670G mutant eyes (Figure 3). By 5 months of age, over 4 months post-injection, a 
representative ERG trace for the maximum rod-cone scotopic ERG setting for an untreated 
mutant eye presents a full loss of all visual response (Figure 3A). However, the treated eye 
retained a strong visual response (Figure 3A), although with a lower b-wave amplitude 
(approximately 100µV) than that of a control wild-type B6 mouse, but comparable to the 
amplitude of the P5 treated Pde6αD670G eye (Figure 3A). There was a loss of the a-wave 
amplitude in the treated eyes as well, suggesting a loss of some of the photoreceptor cells. 
Quantification of the cohort of mice detected rod-cone maximum scotopic visual 
responses for the Pde6αD670G treated eyes at approximately 1/3 of the response of wild-type B6 
mice, but the treated eyes had significantly increased visual responses compared to the untreated 
fellow eyes (Figure 3D). The significant increase in visual response for the treated eyes 
remained stable over 6 months, the longest time analyzed in this study (Figure 3D).  
 Furthermore, since PDE6α mutations lead to a rod-cone dystrophic disease, we examined 
the loss of the a-wave amplitude seen in the maximum rod-cone scotopic ERG traces for the 
Pde6αD670G treated mice compared to wild-type B6 mice (Figure 3A). Dim light, scotopic ERGs, 
recording responses from rod photoreceptor cells, did not display visual responses in either the 
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P21 Pde6αD670G treated or untreated eyes compared to a B6 control mouse (Figure 3B). We 
found that only 3 P21 Pde6αD670G treated eyes had rod-only ERG recordings, and the later 
delivery of the gene therapy virus may prevent any rod cell functional response detected by the 
ERG. However, quantification from 2 to 6 months of age for Pde6αD670G mice given a single 
subretinal injection of AAV2/8(Y733F)-Rho-Pde6α at both P5 and P21 displayed a-wave 
amplitudes at approximately 1/6 of the B6 mouse a-wave response, but significantly increased 
compared to the untreated fellow eyes for 4 months of age, although this visual response was 
barely increased over the untreated fellow eyes at both 5 and 6 months of age (Figure 3E). 
 For human RP patients, the loss of the peripheral visual field has already begun when 
they first present to an eye care professional. The loss of the cone photoreceptor cells, giving the 
central visual field, is important for performing daily activities. Therefore, even if only a 
relatively small amount of rod cells survive, and these cells are able to provide a barely 
detectable visual response, cone cells still have the possibility of surviving and remaining healthy 
in the treated eyes. We tested for cone cell function in the Pde6αD670G mice given a single 
subretinal injection of AAV2/8(Y733F)-Rho-Pde6α at P21 using the photopic ERG setting. 
Representative photopic ERG responses at 5 months of age did not detect visual function in the 
untreated Pde6αD670G eyes (Figure 3C). In contrast, the treated Pde6αD670G eyes had a similar 
cone-specific ERG response to that of the B6 control eyes (Figure 3C). Quantification of the 
cone cell ERG responses were significantly improved in the treated Pde6αD670G eyes compared 
the untreated fellow eyes for the 6 months examined (Figure 3F). Additionally, cone cell visual 
function is sustained in the treated Pde6αD670G mutant eyes, at approximately half the response of 
wild-type B6 eyes, for all 6 months examined (Figure 3F). Taken together, our data suggests 
that treatment with AAV2/8(Y733F)-Rho-Pde6α, even after the onset of degeneration, rescues 
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cone photoreceptor cell survival and both cone-specific and maximum visual response for at 
least 6 months in the Pde6αD670G mutant mice. 
 
 
Figure 3. Rescued visual function after AAV2/8(Y733F)-Rho-Pde6α transduction. 
Representative scotopic maximum ERG traces for a B6 control mouse (blue), a P5 treated eye 
(red), a P21 treated eye (green) and an untreated eye (purple) of a Pde6αD670G mouse at 5 months 
of age (A). Representative scotopic dim light rod-specific ERG traces of a B6 control mouse 
(blue), a P5 treated eye (red), a P21 treated eye (green) and an untreated eye (purple) of a 
Pde6αD670G mouse at 5 months of age (B), and representative photopic single flash cone-
mediated ERG traces for a B6 control mouse (blue), a P5 treated eye (red), a P21 treated eye 
(green) and an untreated eye (purple) of a Pde6αD670G mouse at 5 months of age (C). Maximum 
scotopic b-wave amplitudes in a B6 mouse, the treated Pde6αD670G eyes and fellow-untreated 
eyes monthly between 2 and 6 months of age (D). Maximum scotopic photoreceptor-mediated a-
wave amplitudes (shown as positive values) in a B6 mouse, the treated Pde6αD670G eyes and 
fellow-untreated eyes monthly between 2 and 6 months of age (E). Photopic cone-specific b-
wave amplitudes in a B6 mouse, the treated Pde6αD670G eyes and fellow-untreated eyes from 2 to 
6 months of age (F). Error bars show SEM for each time point and the significance was 
calculated for the P21 treated eyes compared to untreated fellow eyes using the ratio paired t-test 
analysis. N≥ 3 mice. *p < 0.05; **p < 0.01; ***p < 0.001. 
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Despite gene delivery at mid-stage of disease, long-term delay of retinal pigment epithelial 
degeneration in treated Pde6αD670G mutant eyes 
 Since a single subretinal injection of AAV2/8(Y733F)-Rho-Pde6α after disease onset can 
protect the survival and visual function of the cone photoreceptor cells, we tested whether it can 
rescue the secondary retinal pigment epithelial (RPE) degeneration visible upon fundus 
examination in RP patients. We examined infrared (IR) images of P21 treated and fellow 
untreated Pde6αD670G mutant eyes from 5 to 8 months of age. Representative IR images of a 
mutant Pde6αD670G eye over time displays a relatively normal fundus at 5 months of age (Figure 
4A). However, a mottled, degenerative appearance begins at 6 months of age and continues to 
substantially increase through 8 months of age, the last time analyzed (Figure 4C, E, and G; 
asterisks). In comparison, the gene therapy treated Pde6αD670G mutant eyes, after the onset of 
disease, display a normal, healthy retinal image from 5 to 8 months of age (Figure 4B, D, F, and 
H) similar to a B6 control at 6 months of age (Figure 4I). 
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Figure 4. Delay of retinal pigment epithelial atrophy after AAV2/8(Y733F)-Rho-Pde6α 
transduction. Representative infrared (IR) images of an untreated Pde6αD670G mutant eye at 5 
(A), 6 (C), 7 (E) and 8 (G) months of age compared with the fellow-treated Pde6αD670G mutant 
eye at 5 (B), 6 (D), 7 (F) and 8 (H) months of age. Images for all time points are taken from the 
same mouse. Representative IR image of a C57BL/6J control mouse at 6 months of age (I). 
Increased IR reflectance represents RPE atrophy (*). IR imaging was obtained at 790 nm 
absorption and 830 nm emission using a 55° lens. Images were taken of the central retina, with 
the optic nerve located at the center of the image and the site of the subretinal bleb along the 
lower left-hand quadrant. 
 
DISCUSSION 
Our previous studies have proven efficacy of the AAV2/8(Y733F)-Rho-Pde6α virus after 
subretinal injection in the pre-clinical model of RP before the onset of degeneration (152). By 
genetically enhancing rod PDE6α activity, we were able to restore rod function and therefore 
prevent the progressive cell-autonomous loss of the rods for up to 11 months of age. 
Additionally, we prevented the subsequent non-cell-autonomous loss of the cone photoreceptors 
and the secondary disease effects found in human RP patients. We also provided evidence that 
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the visual rescue noted in our previous manuscript was due to the Pde6α transgene delivery after 
subretinal injection of the AAV2/8(Y733F)-Rho-Pde6α virus, as mice given subretinal injections 
of AAV2/8(Y733F)-TurboRFP, without the Pde6α transgene, did not show any visual rescue at 
6 weeks of age, and had a reduced response in comparison to their uninjected fellow eyes (152). 
In the majority of the current pre-clinical animal models for RP gene therapy, the delivery of the 
virus has been performed before the onset of disease (84-85, 124-125, 131, 144, 152). This 
proves the efficacy of the gene therapy vector in halting the presentation of disease, but it does 
not mimic human scenarios. Since every newly diagnosed RP patient already exhibits significant 
loss of rods and cones in their peripheral retinas, gene therapy intervention must be able to 
rescue photoreceptor cells after degeneration onset. 
Therefore, we proposed experiments to address the clinically important question of 
whether visual function can be rescued in retinas with grossly advanced disease. Human patients 
are typically diagnosed during mid-stage photoreceptor degeneration, and we injected the 
AAV2/8(Y733F)-Rho-Pde6α virus at post-natal (P) day 21 to match this time-point in the pre-
clinical model. In the mouse, approximately half of the ONL layer has been lost by P21 (Figure 
1A). Retinal whole mount imaging displayed AAV2/8(Y733F) uptake into the retina localized at 
the site of the subretinal bleb, as would be expected (Figure 1B). The diseased retina does not 
have an immune response against the AAV and its transgenic product after delivery, and allows 
for a similar spread, accounting for the uptake of the virus in approximately 20-30% of the 
retinal photoreceptor cells, in the fully developed eye as was seen in the mouse eye after a P5 
injection of the AAV2/8(Y733F)-TurboRFP (152). Additionally, studies have shown that the full 
development of the extracellular matrix could block the viral spread from transducing as many 
photoreceptor cells as it can affect when injected at 2 weeks of age or earlier (154-156). The size 
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of the red fluorescent protein (RFP) expression in our study suggests that the development of the 
extracellular matrix does not block the viral spread after subretinal injection at P21.  
Human clinical trials for Leber congenital amaurosis (LCA), utilizing the AAV2 serotype 
for gene therapy, are currently ongoing (NCT00999609; NCT00821340; NCT01496040; 
NCT00481546). Although these trials have been effective in restoring visual responses, it has 
been a concern that the human body will produce antibodies after it detects the presence of the 
AAV vector. However, in our study, western blot analysis for the presence of antibodies against 
PDE6α 2 months after delivery of the gene therapy virus did not suggest an immune response in 
the host (Figure 1C). Phase I safety trials typically enroll 3 patients to test for adverse safety 
events, and therefore we used a sample size of 5 mice to test for this potential immune reaction.  
We propose that although systemic delivery of AAV2/8(Y733F) may be able to induce 
neutralizing antigens, subretinal injection of the gene therapy virus allowed for the host immune 
response to remain deactivated. However, it is possible that the immune response may induce 
neutralizing antibodies after subretinal injection of the gene therapy virus, but it is not at the 
threshold response that can be detected with our immunoblot analysis. It is still necessary to 
conduct a Phase I safety trial when delivering gene therapy to human patients, along with a 
dosage trial, in case of species-related differences in the immune response between the mice and 
the humans.  
Current clinical trials suggest that the eye is immune-privileged enough that a secondary 
injection into the contralateral eye is safe and effective and does not provoke the immune system 
(58, 76, 78, 161). Whether or not a second injection into the same eye would be possible without 
rejection of the gene therapy virus is something that still needs to be determined. This data 
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suggests that AAV2/8(Y733F) may be used in human patients without an immune reaction for at 
least a single injection procedure and is a useful gene therapy virus for future clinical studies.  
Since the AAV2/8(Y733F)-Rho-Pde6α safely functioned in the diseased retinal 
environment, the rescued photoreceptor cells and visual function is promising for patients who 
have been diagnosed after mid-stage of RP. However, rod photoreceptor cell visual function was 
barely detectable upon ERG analysis in our study, for both P5 and P21 treated mutant eyes. P5 
treated eyes had a significant increase in rod cell function, although at approximately 1/6 of the 
response of a wild-type B6 mouse for the 6 month study period, as previously published (152). 
However, P21 treated mutant eyes had a significant increase in rod cell function for 4 months of 
age, but no significant difference at both 5 and 6 months of age (Figure 3). This may be due to 
the delivery of the gene therapy virus into a retina where rod cells have reached the stage of no 
return. There may be a threshold of rod cells remaining in the retina for the ERG to be able to 
detect a response, and the amount transduced by the viral vector at the site of the subretinal bleb 
may not be strong enough for a detectable visual response. Not achieving a minimum number of 
rescued rods is likely to cause non-autonomous death of rescued rods (162-164). However, even 
in the worst-case scenario, if the AAV2/8(Y733F)-Rho-Pde6α virus is unable to rescue rod 
photoreceptor cell function after delivery during degeneration; we still found significant cone 
cell survival and visual responses (Figure 2-3). The cone cells contribute to the maximal mixed 
scotopic ERG responses, which explain their significant rescue in the P21 treated eyes over the 
6-month study period. Furthermore, cone cell visual function persisted without decline through 
the 6-month study period, suggesting that this long-term rescue is as beneficial when the gene 
therapy virus is delivered during the mid-stage of photoreceptor neurodegeneration as it is when 
delivered before the onset of disease (85, 152).  
113 
 
 
Overall, the AAV2/8(Y733F)-Rho-Pde6α virus is able to protect cone cell function, 
however, it appears that the protection of the rod cells will depend on how many rod 
photoreceptors remain at the time of gene therapy delivery. Since many RP patients initially 
present with considerable degeneration, earlier treatment may produce more favorable outcomes. 
It still remains to be determined when a threshold may be met where there is no longer the 
possibility to rescue the cone cells, but this study shows that at the point when patients are 
diagnosed by clinicians, mid-stage degeneration, it is still possible to halt secondary cone cell 
degeneration. 
Although the rod cell survival and function declined compared to a B6 wild-type mouse, 
the gene therapy treatment with the AAV2/8(Y733F)-Rho-Pde6α virus at P21 is able to protect 
against the secondary disease effects of RP. RP is characterized as a rod-cone dystrophic disease, 
where the rod cells undergo degeneration and this is followed by the secondary loss of the cone 
cells. Furthermore, secondary effects to the loss of the photoreceptors, both the rods and the 
cones, occur in RP patients, such as the atrophy of the retinal pigment epithelial (RPE) cell layer 
and remodeling of the retina. The protection of the cone cell survival and overall function with 
the AAV2/8(Y733F)-Rho-Pde6α virus treatment at P21 is able to provide protection against the 
later secondary effects of RP, such as the RPE atrophy, for at least 8 months of age.  
The first human gene therapy trial for Leber congenital amaurosis (LCA) reported 
enhanced visual function for at least 3 years in approximately 33-50% of patients (165-167). This 
was profoundly encouraging given that these 4 phase-1 safety trials only enrolled patients with 
end-stage disease (no visual function). However, a follow-up study revealed that the gene therapy 
failed to halt, or even slow, photoreceptor degeneration (157). Treatment failure may be due to 
insufficient or inefficient vector transduction due to the AAV2 serotype. Our current report is the 
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first study to analyze gene therapy treatment after disease onset in a model with a mutation 
within the rod photoreceptor cell. Our study suggests that the AAV2/8(Y733F) vector has the 
ability to efficiently transduce the photoreceptor cells (20-30% transduced) after subretinal 
injection, even within an already diseased retina. However, in agreement with the follow-up 
study, we found that there may be a point of no return for the rod cell rescue (157). Rod cells are 
present at 3 weeks of age, the age of treatment with the gene therapy virus, but these cells appear 
to lose their visual function as shown in the ERG results of this study (Figure 3). 
When first seen by a health care professional, PDE6 patients have peripheral vision loss – 
both night and daytime forms, which are manifestations of peripheral rod and cone degeneration, 
respectively. PDE6 is expressed in rods, but not cones. Cone loss, on the other hand, is due to 
secondary, non-cell-autonomous effects. Mid-stage gene therapy administration cannot halt the 
progressive cell-autonomous degeneration of rods but can prevent the secondary subsequent, non-
cell-autonomous cone loss. 
Therefore, we found that although rod photoreceptor cells may succumb to degeneration, 
the AAV2/8(Y733F)-Rho-Pde6α virus is able to provide long-term rescue and function of the 
cone cells and delayed secondary effects of RP disease, such as the atrophy of the retinal 
pigment epithelium (RPE). This lasted for at least a quarter of the mouse lifespan, the longest 
time-point studied in this analysis. Furthermore, cone cell survival and visual function were 
similar to the rescue effects found when gene therapy is delivered prior to disease onset. Thus, 
even when delivered after degeneration onset, the AAV2/8(Y733F)-Rho-Pde6α virus can be a 
useful gene therapy vector to provide long-term cone cell survival and function for human 
patients with RP caused by mutations in PDE6A. 
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MATERIALS AND METHODS 
Mouse lines and husbandry 
C57BL/6J-Pde6αnmf363/nmf363, with a D670G mutation, herein referred to as Pde6αD670G, 
mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Mice were maintained 
in the Columbia University Pathogen-free Eye Institute Annex Animal Care Services Facility 
under a 12/12-h light/dark cycle. All experiments were approved by the local Institutional 
Animal Care and Use Committee (IACUC) under protocol #AAAF-2107. Mice were used in 
accordance with the Statement for the Use of Animals in Ophthalmic and Vision Research of the 
Association for Research in Vision and Ophthalmology, as well as the Policy for the Use of 
Animals in Neuroscience Research of the Society for Neuroscience. Pde6αD670G mice used in this 
study were bred from a colony of mice that has been previously reported (121). Pde6αD670G are 
coisogenic in the C57BL/6J (B6) background; therefore, age-matched B6 mice were used as 
experimental controls (The Jackson Laboratory).  
 
Construction of AAV vectors 
AAV serotype 2/8 capsids containing a point mutation in surface-exposed tyrosine 
residues, AAV2/8(Y733F), exhibit higher transduction efficiency in photoreceptors and a faster 
onset of expression than other AAV serotypes when delivered into the subretinal space of the eye 
(85). Therefore, these vectors were used for packaging our Pde6α construct. Vector plasmids 
were constructed by inserting 1.1 kb of the murine rhodopsin promoter region [Ensembl, 
rhodopsin, chromosome 6: (115, 930, 881–115, 931, 988); Ensembl, rhodopsin, ATG = 1: 
(−1125, −17)] and a full-length murine Pde6α cDNA fragment into the pZac2.1 plasmid to 
generate pZac2.1.mRhodopsin.mPde6α.SV40 (150). AAV vectors were created, packaged and 
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purified at the Penn Vector Corporation, to become 
AAV2/8(Y733F).mRhodopsin.mPde6α.SV40 (University of Pennsylvania, PA, USA). The 
AAV2/8(Y733F).mRhodopsin.mPde6α.SV40 vector will be referred to as AAV2/8(Y733F)-
Rho-Pde6α in this publication. AAV2/8.CMV.TurboRFP.RBG was purchased from the Penn 
Vector Corporation as the AAV serotype control and will be referred to as AAV2/8-TurboRFP 
in this publication.  
 
Transduction of AAV vectors 
To increase levels of wild-type PDE6α, we injected AAV2/8(Y733F)-Rho-Pde6α (0.7µl, 
1.26e13 genome copy (GC)/ml) into the subretinal space of the right eye of Pde6αD670G mice at 
either post-natal day (P) 5 or P21. AAV2/8-TurboRFP (0.7 µl, 7.28e12 GC/ml) was injected into 
the subretinal space of the right eye of Pde6αD670G mice at P21 for control experiments. Virus 
particles were injected at the 6 o'clock position of the eye, ∼1.5 mm from the limbus, to produce 
a subretinal bleb in the mid-periphery of the retina. The left eyes of all mice were kept as a 
matched control for experimental analyses. Anesthesia and surgery were performed as previously 
described (87, 131).  
 
Whole mount analysis 
Mice were euthanized according to the established IACUC guidelines. Eyes were 
enucleated and placed in 2% paraformaldehyde for 1 h at room temperature. The optic nerve, 
cornea and lens were removed. The whole eyecup was then flattened by means of four radial cuts 
extending out from the optic nerve and mounted with mounting medium (Vectashield, 
Burlingame, CA, USA). RFP visualization was achieved by fluorescence microscopy, and 
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bright-field imaging was used to visualize the whole retina (Leica DM 5000B microscope). 
Pictures were taken at 2.5× magnification using the Leica Application Suite Software (Leica 
Microsystems Inc., Germany).  
 
Immunoblot analysis 
A B6 retina was homogenized in 10% sodium dodecyl sulfate (SDS) by brief sonication 
and denatured at 100°C for 5 min. Following centrifugation, the total protein content per sample 
was measured using the DC protein assay method (Bio-Rad Laboratories, Hercules, CA, USA). 
Proteins were separated by SDS polyacrylamide gel electrophoresis. The samples were then 
transferred to nitrocellulose membranes, which were blocked in 3% bovine serum albumin 
(BSA; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 150 mmol/l NaCl, 100 mmol/l Tris 
(pH 7.4) and 0.5% Tween-20 (BSA-TTBS). Membranes were incubated with either blood serum 
from a treated Pde6αD670G mouse (1:15), blood serum from an untreated Pde6αD670G mouse 
(1:15), or anti-PDE6α (1:300, Abcam) as primary antibodies in BSA-TTBS. After washing in 
TTBS, filters were incubated with goat anti-rabbit or goat anti-mouse-conjugated horseradish 
peroxidase secondary antibodies (1:20 000, Santa Cruz Biotechnology). After washing, antibody 
complexes were visualized by a chemiluminescence detection kit (Immobilon Western, Millipore 
Corporation, Billerica, MA, USA) and a Kodak BioMax film (Kodak, Rochester, NY, USA). 
 
Infrared Imaging 
IR fundus imaging was obtained with the Spectralis scanning laser confocal 
ophthalmoscope (Heidelberg Engineering, Carlsbad, CA, USA). IR imaging was obtained at 790 
nm absorption and 830 nm emission using a 55° lens. Images were taken of the central retina, 
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with the optic nerve located in the center of the image and the site of the subretinal bleb along 
the lower left-hand quadrant.  
 
Histochemical analyses 
Mice were sacrificed and the eyes enucleated as previously described (133). Excalibur 
Pathology, Inc. prepared Hematoxylin & Eosin retinal sections. The morphology of 
photoreceptors and the amount of photoreceptor cell nuclei of AAV2/8(Y733F)-Rho-Pde6α-
treated eyes were compared with the untreated fellow eyes. Quantification of photoreceptor 
nuclei was conducted on several sections that contained the optic nerve, as follows: the distance 
between the optic nerve and the ciliary body was divided into four, approximately equal, 
quadrants. Three columns of nuclei (how many cell nuclei thick) were counted within each 
single quadrant. These counts were then used to determine the average thickness of the ONL for 
each individual animal at each time. For the treated eyes, the rescued half of the treated retina 
between the optic nerve and the ciliary body was quantified in this manner, with the opposite 
side of the retina, between the optic nerve and the ciliary body, being quantified similarly and 
considered the unrescued half of the treated mutant eye (the internal control). Averages and 
standard deviations were calculated from animals for each time point using paired t-test 
statistical analyses with statistical significance set at P < 0.05. Sectioning proceeded along the 
long axis of the segment, so that each section contained upper and lower retina as well as the 
posterior pole. 
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Electroretinograms 
Mice were dark-adapted overnight, manipulations were conducted under dim red light 
illumination, and recordings were made using Espion ERG Diagnosys equipment (Diagnosys 
LLL, Littleton, MA, USA). Adult B6 control mice were tested at the beginning of each session to 
ensure equal readouts from the electrodes for both eyes before testing the experimental mice. 
Pupils were dilated using topical 2.5% phenylephrine hydrochloride and 1% tropicamide (Akorn 
Inc., Lakeforest, IL, USA). Mice were anesthetized by intraperitoneal injection of 0.1 ml/10 g 
body weight of anesthesia [1 ml ketamine 100 mg/ml (Ketaset III, Fort Dodge, IA, USA) and 0.1 
ml xylazine 20 mg/ml (Lloyd Laboratories, Shenandoah, IA, USA) in 8.9 ml PBS]. Body 
temperature was maintained at 37°C using a heating pad during the procedure. Hand-made 
electrodes were placed upon the corneas and gonioscopic prism solution (Alcon Labs, Inc., Fort 
Worth, TX, USA) was applied to each eye. Both eyes were recorded simultaneously. A total of 
40–60 responses were averaged for each trial. All further detail on the ERG method has been 
described previously (134-135). We measured scotopic dim light maximal b-wave ERG 
responses to assess rod-only responses, scotopic maximal b-wave ERG responses to assess inner 
retina function, scotopic maximal a-wave ERG responses to assess photoreceptor-specific 
function, and photopic maximal b-wave ERG responses to assess cone-specific function. 
Maximal responses were taken from the Espion readout in microvolts and quantified using ratio 
paired t-test statistical analyses with statistical significance set at P < 0.05.  
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Chapter 6: Conclusions and Future Directions 
PART I: CONCLUSIONS 
 This study began by establishing the temporal and biochemical characteristics of 
photoreceptor neurodegeneration in a murine model of retinitis pigmentosa (RP) with a mutation 
in the alpha subunit of the rod-specific cyclic guanosine monophosphate (cGMP) 
phosphodiesterase 6 (PDE6): the Pde6αnmf363 mutant mice. We proposed to determine whether or 
not these were a useful pre-clinical model to test therapies, such as gene therapy, for human 
clinical trials. Our study utilized non-invasive live imaging technology alongside standard 
sacrificial experiments to establish the time-course of degeneration in the Pde6αnmf363 pre-clinical 
model of RP (Figure 1). We found that photoreceptor cells undergo complete degeneration by 4 
months of age, and that the secondary retinal pigment epithelial (RPE) atrophy seen in human RP 
patients begins after 5 months of age. This study determined that the time most useful for 
examining therapeutic benefit is after 4 months of age, when it will be clear whether or not any 
photoreceptor cells have survived due to the therapy. For the secondary effects, we found that the 
best analysis takes place after 5 months of age in this pre-clinical model. This study suggests that 
the Pde6αnmf363 mutant mice have similar biochemical characteristics of RP to that of human RP 
patients, and the disease progresses in a similar pattern as well.  It will allow for research to be 
conducted in a timely and cost-effective manner to test potential therapeutic options for clinical 
trials in human RP patients with a mutation in PDE6A. 
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Figure 1. Timeline of Retinal Degeneration in the Pde6αD670G Mice. Primary rod cell 
degeneration at 2 weeks of age is followed by the secondary degeneration of the cone cells at 1 
month of age. This continues until global visual function is undetectable by electrophysiological 
measurements at 2 months of age, and all photoreceptor cell nuclei (both the rods and cones) are 
undetected upon histological examination by 4 months of age. Secondary remodeling, such as 
the atrophy of the retinal pigment epithelium, develops beginning at 5 months of age. This 
degeneration continues throughout the lifespan of the mouse (approximately 2-2.5 years). 
 
 Secondly, we proposed to rescue the visual function of the Pde6αnmf363 pre-clinical model 
using gene therapy. However, before beginning our analysis we needed to determine the best and 
most consistent method to deliver the gene therapy vector to the photoreceptor cells. We 
developed a method for the subretinal injection surgical procedure, to precisely and accurately 
deliver the gene therapy virus, or other potential therapeutic treatments, to the location between 
the RPE and the photoreceptor cells. The development of this technique, and video for 
instruction to other researchers, allows for each mouse given a subretinal injection to be 
comparable to one another. It provides researchers with a standard method of completing the 
subretinal injection surgical procedure successfully, and ensuring that the gene therapy vector or 
stem cells are placed in the location necessary to efficiently treat the ophthalmic disease.  
 Once we established a standard practice for performing the subretinal injection surgical 
procedure, we then cloned a gene therapy virus for use in treating the Pde6αnmf363 pre-clinical 
mouse model. In 2011, the first attempt at using AAV2/8 gene therapy to functionally rescue 
mouse models of RP, in particular one Pde6β mouse model, showed long-term rescue effects for 
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6 months of age in the mouse (85).  However, no studies have been conducted on animal models 
with mutations in the α-subunit of PDE6 to ameliorate the disease progression.  
We applied AAV-based gene therapy that can rescue photoreceptor degeneration and 
restore neuronal function in a Pde6αnmf363 mouse model of recessive RP. We demonstrated that 
after a single subretinal injection of AAV2/8(Y733F)-Rho-Pde6α into the Pde6αnmf363 mouse, the 
phenotype can be both structurally and functionally rescued for at least 11 months of age; half of 
the mouse lifespan. We found that subretinal injection of the AAV2/8(Y733F)-Rho-Pde6α virus 
caused the virus to remain localized to the site of the subretinal bleb, only transducing 
approximately 20-30% of the photoreceptor cells. However, despite focal rescue of retinal 
structure adjacent to the injection site, we achieved remarkable global functional restoration as 
assessed by ERG that lasted over 9 months of age, almost half of the mouse lifespan.  
Additionally, infrared (IR) imaging showed extensive RPE atrophy in untreated mutant 
eyes, but healthy fundus images of the fellow treated mutant eyes through 11 months of age; half 
of the mouse lifespan. Although only half of the retina retains photoreceptor cells after subretinal 
injection, it appears that these cells are enough to protect the treated eye from the secondary 
remodeling effects that occur after photoreceptor cell death in RP, such as RPE atrophy. 
Ultimately, the results from this study demonstrate the potential for using gene therapy 
modifications to treat human patients with RP caused by PDE6A mutations.  
Our previous study determined that the AAV2/8(Y733F)-Rho-Pde6α virus was 
efficacious at promoting photoreceptor cell survival and visual function in the pre-clinical model 
of RP. However, we delivered the gene therapy virus at post-natal (P) day 5 in the mouse, at a 
time when RP degeneration has not yet occurred. In contrast, most human patients with RP are 
not clinically diagnosed by a physician until they have lost part of their peripheral visual field, 
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meaning that degeneration of the rod photoreceptor cells has already begun in these patients. It 
was noted that current human clinical trials using gene therapy to treat an RPE mutation does not 
slow the rate of degeneration in the treated patients (157). We proposed to address the clinically 
important question of whether visual function can be rescued in diseased retinas, as would be 
applicable to treating the majority of human RP patients. 
Our follow-up study utilized the same gene therapy virus, AAV2/8(Y733F)-Rho-Pde6α, 
but instead of subretinally injecting the virus at P5 before the disease onset, we now delivered 
the virus at P21, when there is a loss of approximately half of the photoreceptor cell nuclei. We 
determined that subretinal injection of AAV2/8(Y733F)-Rho-Pde6α at P21 does not activate the 
immune response, and is safe for delivery in the pre-clinical model of RP. On the other hand, rod 
cell function was significantly increased over the untreated eye for 4 out of the 6 months studied, 
and delivery of the gene therapy virus at P21 may not achieve the threshold rescue of rod 
photoreceptor cells needed to detect a strong visual response. However, cone cell visual function 
persisted without decline through the six month study period, suggesting that this long-term 
rescue is as beneficial when the gene therapy virus is delivered during the mid-stage of 
photoreceptor neurodegeneration, as it is when delivered before the onset of disease (85, 152). 
This current study suggests that the AAV2/8(Y733F) vector has the ability to efficiently 
transduce the photoreceptor cells after subretinal injection, even within an already diseased 
retina. Although rod photoreceptor cells may succumb to degeneration even after gene therapy 
treatment, the AAV2/8(Y733F)-Rho-Pde6α virus is able to provide long-term rescue and 
function of the cone cells and can delay the secondary effects of RP disease, such as the atrophy 
of the retinal pigment epithelium (RPE). Since the AAV2/8(Y733F)-Rho-Pde6α safely 
functioned in the diseased retinal environment, the rescued photoreceptor cells and visual 
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function is promising for patients with RP caused by mutations in PDE6A who have been 
diagnosed after mid-stage of disease. Overall, our studies established a useful pre-clinical model 
of RP caused by mutations in PDE6A, a consistent method for delivering therapeutic treatments 
to this model, a potential gene therapy virus for future use in human clinical trials.  
 
PART II: FUTURE DIRECTIONS 
 Our studies have determined that the AAV2/8(Y733F)-Rho-Pde6α virus is both safe and 
effective at rescuing photoreceptor cell survival, visual function, and preventing secondary 
disease effects in the pre-clinical model of RP, even when it is delivered after the disease onset. 
Therefore, it would be important to begin examining the use of this gene therapy virus for future 
human clinical trials. To get to human clinical trials, there are a few more questions that still 
need to be answered with further analysis. 
To begin, we were able to rescue some, but not all, rod photoreceptor cell ERG function 
with a single subretinal injection of AAV2/8(Y733F)-Rho-Pde6α at P5, but visual function was 
less detectable for the rod cells with a single subretinal injection of AAV2/8(Y733F)-Rho-Pde6α 
after the onset of disease. It may be that this is due to an insufficient or inefficient vector 
transduction after subretinal injection in the majority of the mice; however, it still remains to be 
determined when a threshold may be met where there is no longer the possibility to rescue the 
cone cells. The best next step for gene therapy research is to test the alternative hypothesis that 
the treatment failure found after gene therapy delivery is due to the retinas reaching a “point of 
no return,” and/or that the rescued photoreceptor cells are being killed non-autonomously in the 
diseased retina (168). 
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A newly developed, inducible genetic restoration system could be created to 
pharmacologically reverse the hereditary defect in RP patients. Our laboratory has begun using 
this new system to study the effectiveness of gene therapy on the entire retina at different stages 
of disease (169). To produce a novel system to follow-up my previous studies, a mouse model 
can be created with a “Stop” cassette blocking the expression of Pde6α, and this Stop cassette 
will be flanked by Cre-loxP sites. This mouse can then be intercrossed with the mutant 
Pde6αnmf363 mouse model, to create a Pde6αnmf363/Stop mouse line. These mice would then be 
crossed to an inducible Cre-driver line where a tamoxifen injection will allow for Cre to remove 
the Stop cassette. Removal of the Stop cassette will allow for the wild-type gene expression to 
become present, acting as delivery of the wild-type gene using AAV viruses did in the previous 
mouse studies. Essentially, it delivers the wild-type healthy copy of the gene, but without the 
lessened transduction efficiency of the viral vectors and there will be no need for the invasive 
subretinal injection surgical procedure. 
Until now, no inducible photoreceptor-specific Cre-driver has been available. However, 
our laboratory has created a Pde6γCreERT2 driver (169). This Cre-driver expresses higher levels of 
Cre than Rosa26, which is commonly used for studies in retinal degenerative diseases. 
Additionally, Rosa26 was unable to provide Cre expression in adult mice, whereas Pde6γCreERT2 
allows for the expression of Cre throughout the mouse lifespan. This experimental procedure has 
begun in our laboratory utilizing a preclinical mouse model of retinitis pigmentosa; the 
Pde6βH620Q mouse. This mouse has a slow disease progression, approximately half of the ERG 
response has declined by 6 months of age. This study has allowed for us to determine that there 
may be a critical window of time for gene therapy to be effective, and it would be important to 
perform these experiments in the rapidly degenerating Pde6αnmf363 mouse model. 
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It will take time and work to create these mouse lines and intercross them to achieve the 
Pde6αnmf363/Stop x Pde6γCreERT2 mice. However, activating the therapeutic gene, Pde6α, during 
photoreceptor degeneration at different stages of disease allows for the full analysis of 
pathological features of RP if “gene therapy” is delivered to each cell targeted by Cre. This 
proposed idea will improve gene therapy by using a novel toolkit to identify and study the factors 
that may be limiting efficacy. For example, if a critical treatment window exists, it could be 
determined. If so, human clinical trials would need to focus on finding methods in which to treat 
RP patients before the onset of this critical window. Secondly, if it provides evidence that there 
may be non-cell-autonomous interactions, it would be best for gene therapy to be coupled with 
other therapeutic treatments as a combinatorial approach to treating disease. 
This new method of gene therapy will greatly impact future studies. First, it does not 
have the limitations found in AAV gene therapy viruses, such as packaging constraints or the 
invasive subretinal injection surgical procedure. Therefore, fewer animals will be required for 
significant study results. This will allow for analysis of the cutting edge combinatorial therapy 
approaches that were difficult experiments due to the number of animals needed for each 
therapeutic option being tested (168, 170). Secondly, this is a novel Cre-driver that can now be 
used to test the function of any potential photoreceptor genes found in the European Conditional 
Mouse Mutageneis (EUCOMM) program catalog. It could lead to discoveries of new genes or 
roles for already known genes in retinal degenerative diseases.  
As shown in our studies, the AAV2/8(Y733F)-Rho-Pde6α virus will most likely promote 
more favorable outcomes in younger patients, as they will have more photoreceptors that have 
not degenerated at the time of gene therapy treatment. In an ideal situation, it will be a standard 
practice to provide screening either in young children or pre-natally to look for known mutations 
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in genes that lead to blindness. At the moment, the process is still expensive, but with the ability 
to perform whole genome and whole exome sequencing, even in a pre-natal situation, it is a 
potential practice for the future (163-165). This way, infants found to have mutations that lead to 
recessive RP can be treated immediately with a single subretinal injection of a gene therapy 
virus, and this may halt, or at least slow, the progression of the retinal degenerative disease. 
Currently, newborns are screened for galactocemia, a type of inherited blindness (171-173). 
Thus, in the future, fetal screening will most likely become a practical and common practice. All 
of these are questions and ideas to be both addressed and pursued, respectively, by future studies 
into the field of gene therapy, and in particular gene therapy to treat autosomal recessive RP 
caused by mutations in the alpha subunit of PDE6. 
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